{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:36:41Z","timestamp":1793525801957,"version":"4.5.0"},"reference-count":644,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Alzheimer\u2019s disease (AD) stands as the predominant form of dementia, presenting significant and escalating global challenges. Its etiology is intricate and diverse, stemming from a combination of factors such as aging, genetics, and environment. Our current understanding of AD pathologies involves various hypotheses, such as the cholinergic, amyloid, tau protein, inflammatory, oxidative stress, metal ion, glutamate excitotoxicity, microbiota-gut-brain axis, and abnormal autophagy. Nonetheless, unraveling the interplay among these pathological aspects and pinpointing the primary initiators of AD require further elucidation and validation. In the past decades, most clinical drugs have been discontinued due to limited effectiveness or adverse effects. Presently, available drugs primarily offer symptomatic relief and often accompanied by undesirable side effects. However, recent approvals of aducanumab (\n                    <jats:bold>1<\/jats:bold>\n                    ) and lecanemab (\n                    <jats:bold>2<\/jats:bold>\n                    ) by the Food and Drug Administration (FDA) present the potential in disrease-modifying effects. Nevertheless, the long-term efficacy and safety of these drugs need further validation. Consequently, the quest for safer and more effective AD drugs persists as a formidable and pressing task. This review discusses the current understanding of AD pathogenesis, advances in diagnostic biomarkers, the latest updates of clinical trials, and emerging technologies for AD drug development. We highlight recent progress in the discovery of selective inhibitors, dual-target inhibitors, allosteric modulators, covalent inhibitors, proteolysis-targeting chimeras (PROTACs), and protein-protein interaction (PPI) modulators. Our goal is to provide insights into the prospective development and clinical application of novel AD drugs.\n                  <\/jats:p>","DOI":"10.1038\/s41392-024-01911-3","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:15:32Z","timestamp":1724422532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1226,"title":["Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies"],"prefix":"10.1038","volume":"9","author":[{"given":"Jifa","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3202-2402","authenticated-orcid":false,"given":"Jiaxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"1911_CR1","unstructured":"WHO. A blueprint for dementia research. Geneva: World Health Organization (2022)."},{"key":"1911_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Prim. 7, 33 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1911_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMra0909142","volume":"362","author":"HW Querfurth","year":"2010","unstructured":"Querfurth, H. W. & LaFerla, F. M. Alzheimer\u2019s disease. N. Engl. J. Med. 362, 329\u2013344 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR4","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 19, 1598\u20131695 (2023).","DOI":"10.1002\/alz.13016"},{"key":"1911_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13195-022-01055-y","volume":"14","author":"C Abdelnour","year":"2022","unstructured":"Abdelnour, C. et al. Perspectives and challenges in patient stratification in Alzheimer\u2019s disease. Alzheimers Res. Ther. 14, 112 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","volume":"16","author":"J Cummings","year":"2021","unstructured":"Cummings, J. New approaches to symptomatic treatments for Alzheimer\u2019s disease. Mol. Neurodegener. 16, 2 (2021).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","volume":"20","author":"J Graff-Radford","year":"2021","unstructured":"Graff-Radford, J. et al. New insights into atypical Alzheimer\u2019s disease in the era of biomarkers. Lancet Neurol. 20, 222\u2013234 (2021).","journal-title":"Lancet Neurol."},{"key":"1911_CR8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12304","volume":"17","author":"N Falg\u00e0s","year":"2021","unstructured":"Falg\u00e0s, N., Walsh, C. M., Neylan, T. C. & Grinberg, L. T. Deepen into sleep and wake patterns across Alzheimer\u2019s disease phenotypes. Alzheimers Dement. 17, 1403\u20131406 (2021).","journal-title":"Alzheimers Dement."},{"key":"1911_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","volume":"103","author":"A Atri","year":"2019","unstructured":"Atri, A. The Alzheimer\u2019s disease clinical spectrum: diagnosis and management. Med. Clin. North Am. 103, 263\u2013293 (2019).","journal-title":"Med. Clin. North Am."},{"key":"1911_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s43440-021-00293-5","volume":"73","author":"K Maciejewska","year":"2021","unstructured":"Maciejewska, K., Czarnecka, K. & Szyma\u0144ski, P. A review of the mechanisms underlying selected comorbidities in Alzheimer\u2019s disease. Pharm. Rep. 73, 1565\u20131581 (2021).","journal-title":"Pharm. Rep."},{"key":"1911_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13195-023-01314-6","volume":"15","author":"B Dubois","year":"2023","unstructured":"Dubois, B. et al. Biomarkers in Alzheimer\u2019s disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res. Ther. 15, 175 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR12","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/alz.12792","volume":"19","author":"S Katabathula","year":"2023","unstructured":"Katabathula, S., Davis, P. B. & Xu, R. Comorbidity-driven multi-modal subtype analysis in mild cognitive impairment of Alzheimer\u2019s disease. Alzheimers Dement. 19, 1428\u20131439 (2023).","journal-title":"Alzheimers Dement."},{"key":"1911_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1039\/D3AY01488F","volume":"16","author":"X Gong","year":"2024","unstructured":"Gong, X. et al. A red-emitting mitochondria targetable fluorescent probe for detecting viscosity in HeLa, zebrafish, and mice. Anal. Methods 16, 293\u2013300 (2024).","journal-title":"Anal. Methods"},{"key":"1911_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41392-020-0171-5","volume":"5","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. ALDH2 contributes to melatonin-induced protection against APP\/PS1 mutation-prompted cardiac anomalies through cGAS-STING-TBK1-mediated regulation of mitophagy. Signal Transduct. Target Ther. 5, 119 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13024-022-00576-2","volume":"17","author":"A Salasova","year":"2022","unstructured":"Salasova, A., Monti, G., Andersen, O. M. & Nykjaer, A. Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer\u2019s disease. Mol. Neurodegener. 17, 74 (2022).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR16","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.ajp.2021.102961","volume":"68","author":"VS Marde","year":"2022","unstructured":"Marde, V. S. et al. Alzheimer\u2019s disease and sleep disorders: Insights into the possible disease connections and the potential therapeutic targets. Asian J. Psychiatr. 68, 102961 (2022).","journal-title":"Asian J. Psychiatr."},{"key":"1911_CR17","doi-asserted-by":"publisher","first-page":"101592","DOI":"10.1016\/j.arr.2022.101592","volume":"76","author":"K Fehsel","year":"2022","unstructured":"Fehsel, K. & Christl, J. Comorbidity of osteoporosis and Alzheimer\u2019s disease: Is \u2018AKT \u2018-ing on cellular glucose uptake the missing link? Ageing Res. Rev. 76, 101592 (2022).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR18","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.3390\/ijms23094962","volume":"23","author":"S Gunes","year":"2022","unstructured":"Gunes, S. et al. Biomarkers for Alzheimer\u2019s disease in the current state: a narrative review. Int J. Mol. Sci. 23, 4962 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR19","doi-asserted-by":"publisher","first-page":"101503","DOI":"10.1016\/j.arr.2021.101503","volume":"72","author":"T Song","year":"2021","unstructured":"Song, T. et al. Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer\u2019s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res. Rev. 72, 101503 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR20","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.3390\/ijms20225536","volume":"20","author":"A Lloret","year":"2019","unstructured":"Lloret, A. et al. When does Alzheimer\u2019s disease really start? The role of biomarkers. Int J. Mol. Sci. 20, 5536 (2019).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR21","first-page":"371","volume":"8","author":"AP Porsteinsson","year":"2021","unstructured":"Porsteinsson, A. P. et al. Diagnosis of early Alzheimer\u2019s disease: Clinical practice in 2021. J. Prev. Alzheimers Dis. 8, 371\u2013386 (2021).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1911_CR22","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/S2589-7500(21)00275-2","volume":"4","author":"T Nedelec","year":"2022","unstructured":"Nedelec, T. et al. Identifying health conditions associated with Alzheimer\u2019s disease up to 15 years before diagnosis: an agnostic study of French and British health records. Lancet Digit. Health 4, e169\u2013e178 (2022).","journal-title":"Lancet Digit. Health"},{"key":"1911_CR23","first-page":"313","volume":"8","author":"XX Zhang","year":"2021","unstructured":"Zhang, X. X. et al. The Epidemiology of Alzheimer\u2019s Disease Modifiable Risk Factors and Prevention. J. Prev. Alzheimers Dis. 8, 313\u2013321 (2021).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1911_CR24","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1136\/jnnp-2020-323606","volume":"91","author":"G Logroscino","year":"2020","unstructured":"Logroscino, G. Prevention of Alzheimer\u2019s disease and dementia: the evidence is out there, but new high-quality studies and implementation are needed. J. Neurol. Neurosurg. Psychiatry 91, 1140\u20131141 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1911_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-017-0297-z","volume":"9","author":"M Crous-Bou","year":"2017","unstructured":"Crous-Bou, M., Minguill\u00f3n, C., Gramunt, N. & Molinuevo, J. L. Alzheimer\u2019s disease prevention: from risk factors to early intervention. Alzheimers Res. Ther. 9, 71 (2017).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR26","doi-asserted-by":"publisher","first-page":"680","DOI":"10.15585\/mmwr.mm7120a2","volume":"71","author":"JD Omura","year":"2022","unstructured":"Omura, J. D. et al. Modifiable Risk Factors for Alzheimer Disease and Related Dementias Among Adults Aged \u226545 Years - United States, 2019. MMWR Morb. Mortal. Wkly Rep. 71, 680\u2013685 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1911_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.biopsych.2023.01.011","volume":"93","author":"DF Zhang","year":"2023","unstructured":"Zhang, D. F. & Li, M. Toward a Full Understanding of Causal and Modifiable Risk Factors for Alzheimer\u2019s Disease by Integrative Phenome-wide Association Studies. Biol. Psychiatry 93, 756\u2013758 (2023).","journal-title":"Biol. Psychiatry"},{"key":"1911_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12929-019-0524-y","volume":"26","author":"MVF Silva","year":"2019","unstructured":"Silva, M. V. F. et al. Alzheimer\u2019s disease: risk factors and potentially protective measures. J. Biomed. Sci. 26, 33 (2019).","journal-title":"J. Biomed. Sci."},{"key":"1911_CR29","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/ijms24021059","volume":"24","author":"BK Beata","year":"2023","unstructured":"Beata, B. K. et al. Alzheimer\u2019s Disease-Biochemical and Psychological Background for Diagnosis and Treatment. Int J. Mol. Sci. 24, 1059 (2023).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR30","doi-asserted-by":"publisher","first-page":"101960","DOI":"10.1016\/j.arr.2023.101960","volume":"88","author":"S Thakral","year":"2023","unstructured":"Thakral, S. et al. Alzheimer\u2019s disease: Molecular aspects and treatment opportunities using herbal drugs. Ageing Res. Rev. 88, 101960 (2023).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/biom10010040","volume":"10","author":"GD Stanciu","year":"2019","unstructured":"Stanciu, G. D. et al. Alzheimer\u2019s Disease Pharmacotherapy in Relation to Cholinergic System Involvement. Biomolecules 10, 40 (2019).","journal-title":"Biomolecules"},{"key":"1911_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jalz.2012.05.2116","volume":"8","author":"H Hampel","year":"2012","unstructured":"Hampel, H., Lista, S. & Khachaturian, Z. S. Development of biomarkers to chart all Alzheimer\u2019s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 8, 312\u2013336 (2012).","journal-title":"Alzheimers Dement."},{"key":"1911_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.biopsych.2013.07.031","volume":"75","author":"CL Sutphen","year":"2014","unstructured":"Sutphen, C. L., Fagan, A. M. & Holtzman, D. M. Progress update: fluid and imaging biomarkers in Alzheimer\u2019s disease. Biol. Psychiatry 75, 520\u2013526 (2014).","journal-title":"Biol. Psychiatry"},{"key":"1911_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jalz.2013.04.506","volume":"10","author":"S Lista","year":"2014","unstructured":"Lista, S. et al. CSF A\u03b21-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer\u2019s disease. Alzheimers Dement. 10, 381\u2013392 (2014).","journal-title":"Alzheimers Dement"},{"key":"1911_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrneurol.2017.1","volume":"13","author":"EM Reiman","year":"2017","unstructured":"Reiman, E. M. Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test. Nat. Rev. Neurol. 13, 74\u201376 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1911_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0140-6736(95)90526-X","volume":"345","author":"KL Davis","year":"1995","unstructured":"Davis, K. L. & Powchik, P. Tacrine. Lancet 345, 625\u2013630 (1995).","journal-title":"Lancet"},{"key":"1911_CR37","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1001\/jama.280.20.1777","volume":"280","author":"N Qizilbash","year":"1998","unstructured":"Qizilbash, N. et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists\u2019 Collaboration. JAMA 280, 1777\u20131782 (1998).","journal-title":"JAMA"},{"key":"1911_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.phrs.2016.12.033","volume":"116","author":"B Jarrott","year":"2017","unstructured":"Jarrott, B. Tacrine: In vivo veritas. Pharm. Res. 116, 29\u201331 (2017).","journal-title":"Pharm. Res."},{"key":"1911_CR39","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","volume":"271","author":"PB Watkins","year":"1994","unstructured":"Watkins, P. B. et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer\u2019s disease. JAMA 271, 992\u2013998 (1994).","journal-title":"JAMA"},{"key":"1911_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ejmech.2019.02.005","volume":"166","author":"C de Los R\u00edos","year":"2019","unstructured":"de Los R\u00edos, C. & Marco-Contelles, J. Tacrines for Alzheimer\u2019s disease therapy. III. The PyridoTacrines. Eur. J. Med. Chem. 166, 381\u2013389 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR41","first-page":"CD001190","volume":"6","author":"JS Birks","year":"2018","unstructured":"Birks, J. S. & Harvey, R. J. Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst. Rev. 6, CD001190 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1911_CR42","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/s41401-018-0206-4","volume":"40","author":"X Cui","year":"2019","unstructured":"Cui, X. et al. Donepezil, a drug for Alzheimer\u2019s disease, promotes oligodendrocyte generation and remyelination. Acta Pharm. Sin. 40, 1386\u20131393 (2019).","journal-title":"Acta Pharm. Sin."},{"key":"1911_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1021\/acschemneuro.8b00517","volume":"10","author":"JT Brewster 2nd","year":"2019","unstructured":"Brewster, J. T. 2nd, Dell\u2019Acqua, S., Thach, D. Q. & Sessler, J. L. Classics in Chemical Neuroscience: Donepezil. ACS Chem. Neurosci. 10, 155\u2013167 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"1911_CR44","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/jnnp.2006.099424","volume":"78","author":"HH Feldman","year":"2007","unstructured":"Feldman, H. H. & Lane, R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer\u2019s disease. J. Neurol. Neurosurg. Psychiatry 78, 1056\u20131063 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1911_CR45","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"M R\u00f6sler","year":"1999","unstructured":"R\u00f6sler, M. et al. Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial. BMJ 318, 633\u2013638 (1999).","journal-title":"BMJ"},{"key":"1911_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0006-3223(00)01101-X","volume":"49","author":"J Coyle","year":"2001","unstructured":"Coyle, J. & Kershaw, P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer\u2019s disease. Biol. Psychiatry 49, 289\u2013299 (2001).","journal-title":"Biol. Psychiatry"},{"key":"1911_CR47","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","volume":"60","author":"LJ Scott","year":"2000","unstructured":"Scott, L. J. & Goa, K. L. Galantamine: a review of its use in Alzheimer\u2019s disease. Drugs 60, 1095\u20131122 (2000).","journal-title":"Drugs"},{"key":"1911_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1021\/cr040415t","volume":"106","author":"J Marco-Contelles","year":"2006","unstructured":"Marco-Contelles, J. et al. Synthesis and pharmacology of galantamine. Chem. Rev. 106, 116\u2013133 (2006).","journal-title":"Chem. Rev."},{"key":"1911_CR49","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2165\/00003495-200666110-00015","volume":"66","author":"DM Robinson","year":"2006","unstructured":"Robinson, D. M. & Keating, G. M. Memantine: a review of its use in Alzheimer\u2019s disease. Drugs 66, 1515\u20131534 (2006).","journal-title":"Drugs"},{"key":"1911_CR50","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg, B. et al. Memantine in moderate-to-severe Alzheimer\u2019s disease. N. Engl. J. Med. 348, 1333\u20131341 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR51","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40263-015-0287-2","volume":"29","author":"SL Greig","year":"2015","unstructured":"Greig, S. L. Memantine ER\/Donepezil: A Review in Alzheimer\u2019s Disease. CNS Drugs 29, 963\u2013970 (2015).","journal-title":"CNS Drugs"},{"key":"1911_CR52","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2147\/DDDT.S86463","volume":"10","author":"WJ Deardorff","year":"2016","unstructured":"Deardorff, W. J. & Grossberg, G. T. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer\u2019s disease. Drug Des. Dev. Ther. 10, 3267\u20133279 (2016).","journal-title":"Drug Des. Dev. Ther."},{"key":"1911_CR53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.tips.2020.04.008","volume":"41","author":"O Benek","year":"2020","unstructured":"Benek, O., Korabecny, J. & Soukup, O. A Perspective on Multi-target Drugs for Alzheimer\u2019s Disease. Trends Pharm. Sci. 41, 434\u2013445 (2020).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR54","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40265-020-01268-1","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed, Y. Y. Sodium Oligomannate: First Approval. Drugs 80, 441\u2013444 (2020).","journal-title":"Drugs"},{"key":"1911_CR55","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13195-020-00678-3","volume":"12","author":"T Wang","year":"2020","unstructured":"Wang, T. et al. A phase II randomized trial of sodium oligomannate in Alzheimer\u2019s dementia. Alzheimers Res. Ther. 12, 110 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13195-021-00795-7","volume":"13","author":"S Xiao","year":"2021","unstructured":"Xiao, S. et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer\u2019s dementia. Alzheimers Res. Ther. 13, 62 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR57","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/alz.12444","volume":"18","author":"J Cummings","year":"2022","unstructured":"Cummings, J. & Salloway, S. Aducanumab: Appropriate use recommendations. Alzheimers Dement 18, 531\u2013533 (2022).","journal-title":"Alzheimers Dement"},{"key":"1911_CR58","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon, S. Aducanumab: First Approval. Drugs 81, 1437\u20131443 (2021).","journal-title":"Drugs"},{"key":"1911_CR59","doi-asserted-by":"crossref","unstructured":"Behl, T. et al. \u201cAducanumab\u201d making a comeback in Alzheimer\u2019s disease: An old wine in a new bottle. Biomed. Pharmacother. 148, 112746 (2022).","DOI":"10.1016\/j.biopha.2022.112746"},{"key":"1911_CR60","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jama.2022.24494","volume":"329","author":"HD Larkin","year":"2023","unstructured":"Larkin, H. D. Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA 329, 363 (2023).","journal-title":"JAMA"},{"key":"1911_CR61","first-page":"495","volume":"330","author":"E Harris","year":"2023","unstructured":"Harris, E. Alzheimer Drug Lecanemab Gains Traditional FDA Approval. JAMA 330, 495 (2023).","journal-title":"JAMA"},{"key":"1911_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR63","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"1911_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","volume":"5","author":"H Hippius","year":"2003","unstructured":"Hippius, H. & Neund\u00f6rfer, G. The discovery of Alzheimer\u2019s disease. Dialogues Clin. Neurosci. 5, 101\u2013108 (2003).","journal-title":"Dialogues Clin. Neurosci."},{"key":"1911_CR65","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/diagnostics12122975","volume":"12","author":"R Hajjo","year":"2022","unstructured":"Hajjo, R., Sabbah, D. A., Abusara, O. H. & Al Bawab, A. Q. A Review of the Recent Advances in Alzheimer\u2019s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. Diagnostics 12, 2975 (2022).","journal-title":"Diagnostics"},{"key":"1911_CR66","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/antiox11122402","volume":"11","author":"S Burns","year":"2022","unstructured":"Burns, S. et al. Therapeutics of Alzheimer\u2019s Disease: Recent Developments. Antioxidants 11, 2402 (2022).","journal-title":"Antioxidants"},{"key":"1911_CR67","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1021\/acs.jmedchem.1c01835","volume":"65","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development. J. Med. Chem. 65, 5184\u20135211 (2022).","journal-title":"J. Med. Chem."},{"key":"1911_CR68","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/med.21859","volume":"42","author":"L Feng","year":"2022","unstructured":"Feng, L. et al. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: A review from medicinal chemistry perspectives. Med. Res. Rev. 42, 710\u2013743 (2022).","journal-title":"Med. Res. Rev."},{"key":"1911_CR69","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1021\/acs.jmedchem.1c01714","volume":"65","author":"L Tan","year":"2022","unstructured":"Tan, L. et al. Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. J. Med. Chem. 65, 5149\u20135183 (2022).","journal-title":"J. Med. Chem."},{"key":"1911_CR70","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/cmdc.201900299","volume":"14","author":"GM Silva","year":"2019","unstructured":"Silva, G. M. et al. Allosteric Modulators of Potential Targets Related to Alzheimer\u2019s Disease: a Review. ChemMedChem 14, 1467\u20131483 (2019).","journal-title":"ChemMedChem"},{"key":"1911_CR71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pharmthera.2015.10.002","volume":"156","author":"P Wu","year":"2015","unstructured":"Wu, P., Clausen, M. H. & Nielsen, T. E. Allosteric small-molecule kinase inhibitors. Pharm. Ther. 156, 59\u201368 (2015).","journal-title":"Pharm. Ther."},{"key":"1911_CR72","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","volume":"21","author":"L Boike","year":"2022","unstructured":"Boike, L., Henning, N. J. & Nomura, D. K. Advances in covalent drug discovery. Nat. Rev. Drug Discov. 21, 881\u2013898 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1911_CR73","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","volume":"7","author":"M He","year":"2022","unstructured":"He, M. et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct. Target Ther. 7, 181 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR74","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrd.2016.29","volume":"15","author":"DE Scott","year":"2016","unstructured":"Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat. Rev. Drug Discov. 15, 533\u2013550 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1911_CR75","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/npp.2008.151","volume":"34","author":"LL Blazer","year":"2009","unstructured":"Blazer, L. L. & Neubig, R. R. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology 34, 126\u2013141 (2009).","journal-title":"Neuropsychopharmacology"},{"key":"1911_CR76","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","volume":"4","author":"PP Liu","year":"2019","unstructured":"Liu, P. P., Xie, Y., Meng, X. Y. & Kang, J. S. History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease. Signal Transduct. Target Ther. 4, 29 (2019).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR77","doi-asserted-by":"publisher","first-page":"14499","DOI":"10.3390\/ijms241914499","volume":"24","author":"E Fedele","year":"2023","unstructured":"Fedele, E. Anti-Amyloid Therapies for Alzheimer\u2019s Disease and the Amyloid Cascade Hypothesis. Int. J. Mol. Sci. 24, 14499 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1911_CR78","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1093\/brain\/awad159","volume":"146","author":"KP Kepp","year":"2023","unstructured":"Kepp, K. P. et al. The amyloid cascade hypothesis: an updated critical review. Brain 146, 3969\u20133990 (2023).","journal-title":"Brain"},{"key":"1911_CR79","doi-asserted-by":"publisher","first-page":"784958","DOI":"10.3389\/fpubh.2021.784958","volume":"9","author":"L Rubin","year":"2021","unstructured":"Rubin, L. et al. Genetic Risk Factors for Alzheimer\u2019s Disease in Racial\/Ethnic Minority Populations in the U.S.: A Scoping Review. Front. Public Health 9, 784958 (2021).","journal-title":"Front. Public Health"},{"key":"1911_CR80","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat. Genet. 51, 414\u2013430 (2019).","journal-title":"Nat. Genet."},{"key":"1911_CR81","doi-asserted-by":"publisher","first-page":"104511","DOI":"10.1016\/j.ebiom.2023.104511","volume":"90","author":"SJ Andrews","year":"2023","unstructured":"Andrews, S. J. et al. The complex genetic architecture of Alzheimer\u2019s disease: novel insights and future directions. EBioMedicine 90, 104511 (2023).","journal-title":"EBioMedicine"},{"key":"1911_CR82","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat. Genet. 54, 412\u2013436 (2022).","journal-title":"Nat. Genet."},{"key":"1911_CR83","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease. Mol. Psychiatry 26, 5481\u20135503 (2021).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR84","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pharmthera.2019.03.005","volume":"199","author":"A Eid","year":"2019","unstructured":"Eid, A., Mhatre, I. & Richardson, J. R. Gene-environment interactions in Alzheimer\u2019s disease: A potential path to precision medicine. Pharm. Ther. 199, 173\u2013187 (2019).","journal-title":"Pharm. Ther."},{"key":"1911_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02584-x","volume":"19","author":"RJ Boyd","year":"2022","unstructured":"Boyd, R. J., Avramopoulos, D., Jantzie, L. L. & McCallion, A. S. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J. Neuroinflamm. 19, 223 (2022).","journal-title":"J. Neuroinflamm."},{"key":"1911_CR86","doi-asserted-by":"publisher","first-page":"44659","DOI":"10.1007\/s11356-020-08243-z","volume":"27","author":"MA Rahman","year":"2020","unstructured":"Rahman, M. A. et al. Emerging risk of environmental factors: insight mechanisms of Alzheimer\u2019s diseases. Environ. Sci. Pollut. Res. Int. 27, 44659\u201344672 (2020).","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"1911_CR87","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/brain\/123.3.484","volume":"123","author":"CJ Galton","year":"2000","unstructured":"Galton, C. J., Patterson, K., Xuereb, J. H. & Hodges, J. R. Atypical and typical presentations of Alzheimer\u2019s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 123, 484\u2013498 (2000).","journal-title":"Brain"},{"key":"1911_CR88","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1038\/s41380-022-01531-9","volume":"27","author":"DW Sirkis","year":"2022","unstructured":"Sirkis, D. W. et al. Dissecting the clinical heterogeneity of early-onset Alzheimer\u2019s disease. Mol. Psychiatry 27, 2674\u20132688 (2022).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt155","volume":"5","author":"B Lam","year":"2013","unstructured":"Lam, B. et al. Clinical, imaging, and pathological heterogeneity of the Alzheimer\u2019s disease syndrome. Alzheimers Res. Ther. 5, 1 (2013).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR90","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen, P. S. et al. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimers Res. Ther. 9, 60 (2017).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR91","doi-asserted-by":"publisher","first-page":"9305","DOI":"10.3390\/ijms23169305","volume":"23","author":"X Morat\u00f3","year":"2022","unstructured":"Morat\u00f3, X. et al. Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer\u2019s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. Int. J. Mol. Sci. 23, 9305 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1911_CR92","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe, D. J. Alzheimer\u2019s disease: genes, proteins, and therapy. Physiol. Rev. 81, 741\u2013766 (2001).","journal-title":"Physiol. Rev."},{"key":"1911_CR93","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1126\/science.7058341","volume":"215","author":"PJ Whitehouse","year":"1982","unstructured":"Whitehouse, P. J. et al. Alzheimer\u2019s disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237\u20131239 (1982).","journal-title":"Science"},{"key":"1911_CR94","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1192\/bjp.152.6.737","volume":"152","author":"E Perry","year":"1988","unstructured":"Perry, E. Acetylcholine and Alzheimer\u2019s disease. Br. J. Psychiatry 152, 737\u2013740 (1988).","journal-title":"Br. J. Psychiatry"},{"key":"1911_CR95","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0140-6736(83)91462-9","volume":"1","author":"F Tagliavini","year":"1983","unstructured":"Tagliavini, F. & Pilleri, G. Neuronal counts in basal nucleus of Meynert in Alzheimer disease and in simple senile dementia. Lancet 1, 469\u2013470 (1983).","journal-title":"Lancet"},{"key":"1911_CR96","doi-asserted-by":"publisher","first-page":"10020","DOI":"10.3390\/ijms231710020","volume":"23","author":"J Li","year":"2022","unstructured":"Li, J., Sun, M., Cui, X. & Li, C. Protective Effects of Flavonoids against Alzheimer\u2019s Disease: Pathological Hypothesis, Potential Targets, and Structure-Activity Relationship. Int J. Mol. Sci. 23, 10020 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR97","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0301-0082(02)00079-5","volume":"68","author":"DS Auld","year":"2002","unstructured":"Auld, D. S., Kornecook, T. J., Bastianetto, S. & Quirion, R. Alzheimer\u2019s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 68, 209\u2013245 (2002).","journal-title":"Prog. Neurobiol."},{"key":"1911_CR98","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/molecules27061816","volume":"27","author":"ZR Chen","year":"2022","unstructured":"Chen, Z. R., Huang, J. B., Yang, S. L. & Hong, F. F. Role of Cholinergic Signaling in Alzheimer\u2019s Disease. Molecules 27, 1816 (2022).","journal-title":"Molecules"},{"key":"1911_CR99","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3389\/fnins.2019.00446","volume":"13","author":"XQ Chen","year":"2019","unstructured":"Chen, X. Q. & Mobley, W. C. Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. Front. Neurosci. 13, 446 (2019).","journal-title":"Front. Neurosci."},{"key":"1911_CR100","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel, H. et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 141, 1917\u20131933 (2018).","journal-title":"Brain"},{"key":"1911_CR101","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1093\/brain\/awac096","volume":"145","author":"E Giacobini","year":"2022","unstructured":"Giacobini, E., Cuello, A. C. & Fisher, A. Reimagining cholinergic therapy for Alzheimer\u2019s disease. Brain 145, 2250\u20132275 (2022).","journal-title":"Brain"},{"key":"1911_CR102","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","volume":"25","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh, Z. & Karaman, R. Comprehensive Review on Alzheimer\u2019s Disease: Causes and Treatment. Molecules 25, 5789 (2020).","journal-title":"Molecules"},{"key":"1911_CR103","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","volume":"14","author":"TH Ferreira-Vieira","year":"2016","unstructured":"Ferreira-Vieira, T. H., Guimaraes, I. M., Silva, F. R. & Ribeiro, F. M. Alzheimer\u2019s disease: Targeting the Cholinergic System. Curr. Neuropharmacol. 14, 101\u2013115 (2016).","journal-title":"Curr. Neuropharmacol."},{"key":"1911_CR104","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3390\/ijms22031273","volume":"22","author":"RA Bekdash","year":"2021","unstructured":"Bekdash, R. A. The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer\u2019s Disease. Int. J. Mol. Sci. 22, 1273 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1911_CR105","doi-asserted-by":"publisher","first-page":"105192","DOI":"10.1016\/j.neubiorev.2023.105192","volume":"150","author":"AS Berry","year":"2023","unstructured":"Berry, A. S. & Harrison, T. M. New perspectives on the basal forebrain cholinergic system in Alzheimer\u2019s disease. Neurosci. Biobehav. Rev. 150, 105192 (2023).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1911_CR106","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1515\/revneuro-2019-0089","volume":"31","author":"A Majdi","year":"2020","unstructured":"Majdi, A. et al. Amyloid-\u03b2, tau, and the cholinergic system in Alzheimer\u2019s disease: seeking direction in a tangle of clues. Rev. Neurosci. 31, 391\u2013413 (2020).","journal-title":"Rev. Neurosci."},{"key":"1911_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113168","volume":"152","author":"R Malik","year":"2022","unstructured":"Malik, R. et al. Overview of therapeutic targets in management of dementia. Biomed. Pharmacother. 152, 113168 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1911_CR108","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bios.2016.08.104","volume":"87","author":"FTC Moreira","year":"2017","unstructured":"Moreira, F. T. C., Sale, M. G. F. & Di Lorenzo, M. Towards timely Alzheimer diagnosis: A self-powered amperometric biosensor for the neurotransmitter acetylcholine. Biosens. Bioelectron. 87, 607\u2013614 (2017).","journal-title":"Biosens. Bioelectron."},{"key":"1911_CR109","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider, L. S. et al. Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J. Intern. Med. 275, 251\u2013283 (2014).","journal-title":"J. Intern. Med."},{"key":"1911_CR110","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1093\/brain\/awac181","volume":"145","author":"JC Morris","year":"2022","unstructured":"Morris, J. C. et al. Autosomal dominant and sporadic late onset Alzheimer\u2019s disease share a common in vivo pathophysiology. Brain 145, 3594\u20133607 (2022).","journal-title":"Brain"},{"key":"1911_CR111","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"RJ O\u2019Brien","year":"2011","unstructured":"O\u2019Brien, R. J. & Wong, P. C. Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu. Rev. Neurosci. 34, 185\u2013204 (2011).","journal-title":"Annu. Rev. Neurosci."},{"key":"1911_CR112","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen, G. F. et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharm. Sin. 38, 1205\u20131235 (2017).","journal-title":"Acta Pharm. Sin."},{"key":"1911_CR113","doi-asserted-by":"publisher","first-page":"e1002270","DOI":"10.1371\/journal.pmed.1002270","volume":"14","author":"HM Lanoisel\u00e9e","year":"2017","unstructured":"Lanoisel\u00e9e, H. M. et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 14, e1002270 (2017).","journal-title":"PLoS Med."},{"key":"1911_CR114","doi-asserted-by":"publisher","first-page":"14946","DOI":"10.1523\/JNEUROSCI.4305-10.2010","volume":"30","author":"SW Pimplikar","year":"2010","unstructured":"Pimplikar, S. W. et al. Amyloid-independent mechanisms in Alzheimer\u2019s disease pathogenesis. J. Neurosci. 30, 14946\u201314954 (2010).","journal-title":"J. Neurosci."},{"key":"1911_CR115","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41593-022-01084-8","volume":"25","author":"JH Lee","year":"2022","unstructured":"Lee, J. H. et al. Faulty autolysosome acidification in Alzheimer\u2019s disease mouse models induces autophagic build-up of Abeta in neurons, yielding senile plaques. Nat. Neurosci. 25, 688\u2013701 (2022).","journal-title":"Nat. Neurosci."},{"key":"1911_CR116","doi-asserted-by":"publisher","first-page":"E476","DOI":"10.1073\/pnas.1618657114","volume":"114","author":"L Sun","year":"2017","unstructured":"Sun, L., Zhou, R., Yang, G. & Shi, Y. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A\u03b242 and A\u03b240 peptides by \u03b3-secretase. Proc. Natl Acad. Sci. USA 114, E476\u2013E485 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1911_CR117","doi-asserted-by":"publisher","first-page":"101451","DOI":"10.1016\/j.arr.2021.101451","volume":"71","author":"R Ullah","year":"2021","unstructured":"Ullah, R., Park, T. J., Huang, X. & Kim, M. O. Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer\u2019s pathology: Insights and therapeutic approaches from periphery. Ageing Res. Rev. 71, 101451 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR118","doi-asserted-by":"publisher","first-page":"101212","DOI":"10.1016\/j.arr.2020.101212","volume":"65","author":"S Ayton","year":"2021","unstructured":"Ayton, S. & Bush, A. I. beta-amyloid: The known unknowns. Ageing Res. Rev. 65, 101212 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR119","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"AC Raulin","year":"2022","unstructured":"Raulin, A. C. et al. ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol. Neurodegener. 17, 72 (2022).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR120","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(10)70325-2","volume":"10","author":"PB Verghese","year":"2011","unstructured":"Verghese, P. B., Castellano, J. M. & Holtzman, D. M. Apolipoprotein E in Alzheimer\u2019s disease and other neurological disorders. Lancet Neurol. 10, 241\u2013252 (2011).","journal-title":"Lancet Neurol."},{"key":"1911_CR121","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-pathmechdis-030421-112756","volume":"17","author":"N Koutsodendris","year":"2022","unstructured":"Koutsodendris, N., Nelson, M. R., Rao, A. & Huang, Y. Apolipoprotein E and Alzheimer\u2019s Disease: Findings, Hypotheses, and Potential Mechanisms. Annu. Rev. Pathol. 17, 73\u201399 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"1911_CR122","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrn2620","volume":"10","author":"G Bu","year":"2009","unstructured":"Bu, G. Apolipoprotein E and its receptors in Alzheimer\u2019s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333\u2013344 (2009).","journal-title":"Nat. Rev. Neurosci."},{"key":"1911_CR123","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo, A., Das, S. & Hyman, B. T. APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 20, 68\u201380 (2021).","journal-title":"Lancet Neurol."},{"key":"1911_CR124","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.apsb.2021.10.002","volume":"12","author":"BR Troutwine","year":"2022","unstructured":"Troutwine, B. R. et al. Apolipoprotein E and Alzheimer\u2019s disease. Acta Pharm. Sin. B 12, 496\u2013510 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1911_CR125","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamaneurol.2016.0301","volume":"73","author":"RN Rosenberg","year":"2016","unstructured":"Rosenberg, R. N., Lambracht-Washington, D., Yu, G. & Xia, W. Genomics of Alzheimer Disease: A Review. JAMA Neurol. 73, 867\u2013874 (2016).","journal-title":"JAMA Neurol."},{"key":"1911_CR126","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/WCO.0000000000001242","volume":"37","author":"G Nicolas","year":"2024","unstructured":"Nicolas, G. Recent advances in Alzheimer disease genetics. Curr. Opin. Neurol. 37, 154\u2013165 (2024).","journal-title":"Curr. Opin. Neurol."},{"key":"1911_CR127","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade. J. Alzheimers Dis. 64, S567\u2013S610 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR128","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1515\/REVNEURO.2010.21.2.83","volume":"21","author":"ML Giuffrida","year":"2010","unstructured":"Giuffrida, M. L. et al. The monomer state of beta-amyloid: where the Alzheimer\u2019s disease protein meets physiology. Rev. Neurosci. 21, 83\u201393 (2010).","journal-title":"Rev. Neurosci."},{"key":"1911_CR129","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00401-020-02196-w","volume":"140","author":"SA Kent","year":"2020","unstructured":"Kent, S. A., Spires-Jones, T. L. & Durrant, C. S. The physiological roles of tau and Abeta: implications for Alzheimer\u2019s disease pathology and therapeutics. Acta Neuropathol. 140, 417\u2013447 (2020).","journal-title":"Acta Neuropathol."},{"key":"1911_CR130","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Amyloid beta-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR131","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The Amyloid-\u03b2 Oligomer Hypothesis: Beginning of the Third Decade. J. Alzheimers Dis. 64, S567\u2013S610 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR132","doi-asserted-by":"publisher","first-page":"111575","DOI":"10.1016\/j.biopha.2021.111575","volume":"139","author":"H Yu","year":"2021","unstructured":"Yu, H. & Wu, J. Amyloid-beta: A double agent in Alzheimer\u2019s disease? Biomed. Pharmacother. 139, 111575 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"1911_CR133","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1039\/C6CS00731G","volume":"46","author":"SJ Lee","year":"2017","unstructured":"Lee, S. J. et al. Towards an understanding of amyloid-beta oligomers: characterization, toxicity mechanisms, and inhibitors. Chem. Soc. Rev. 46, 310\u2013323 (2017).","journal-title":"Chem. Soc. Rev."},{"key":"1911_CR134","doi-asserted-by":"publisher","first-page":"e202215785","DOI":"10.1002\/anie.202215785","volume":"62","author":"JH Viles","year":"2023","unstructured":"Viles, J. H. Imaging Amyloid-\u03b2 Membrane Interactions: Ion-Channel Pores and Lipid-Bilayer Permeability in Alzheimer\u2019s Disease. Angew. Chem. Int. Ed. Engl. 62, e202215785 (2023).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1911_CR135","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.pneurobio.2009.01.001","volume":"87","author":"A Salminen","year":"2009","unstructured":"Salminen, A. et al. Inflammation in Alzheimer\u2019s disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 87, 181\u2013194 (2009).","journal-title":"Prog. Neurobiol."},{"key":"1911_CR136","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nbd.2004.12.013","volume":"18","author":"JA White","year":"2005","unstructured":"White, J. A. et al. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol. Dis. 18, 459\u2013465 (2005).","journal-title":"Neurobiol. Dis."},{"key":"1911_CR137","doi-asserted-by":"publisher","first-page":"12463","DOI":"10.1074\/jbc.R109.080895","volume":"285","author":"A Demuro","year":"2010","unstructured":"Demuro, A., Parker, I. & Stutzmann, G. E. Calcium signaling and amyloid toxicity in Alzheimer disease. J. Biol. Chem. 285, 12463\u201312468 (2010).","journal-title":"J. Biol. Chem."},{"key":"1911_CR138","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100241","volume":"37","author":"A Norambuena","year":"2018","unstructured":"Norambuena, A. et al. A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-\u03b2 oligomers. EMBO J. 37, e100241 (2018).","journal-title":"EMBO J."},{"key":"1911_CR139","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.expneurol.2009.03.042","volume":"218","author":"PH Reddy","year":"2009","unstructured":"Reddy, P. H. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer\u2019s disease. Exp. Neurol. 218, 286\u2013292 (2009).","journal-title":"Exp. Neurol."},{"key":"1911_CR140","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.freeradbiomed.2007.09.007","volume":"43","author":"X Wang","year":"2007","unstructured":"Wang, X. et al. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic. Biol. Med 43, 1569\u20131573 (2007).","journal-title":"Free Radic. Biol. Med"},{"key":"1911_CR141","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1089\/ars.2012.5027","volume":"19","author":"DA Butterfield","year":"2013","unstructured":"Butterfield, D. A., Swomley, A. M. & Sultana, R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal 19, 823\u2013835 (2013).","journal-title":"Antioxid. Redox Signal"},{"key":"1911_CR142","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10571-011-9691-4","volume":"31","author":"KC Wilcox","year":"2011","unstructured":"Wilcox, K. C., Lacor, P. N., Pitt, J. & Klein, W. L. A\u03b2 oligomer-induced synapse degeneration in Alzheimer\u2019s disease. Cell Mol. Neurobiol. 31, 939\u2013948 (2011).","journal-title":"Cell Mol. Neurobiol."},{"key":"1911_CR143","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy, J. A. & Higgins, G. A. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256, 184\u2013185 (1992).","journal-title":"Science"},{"key":"1911_CR144","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/d41586-018-05719-4","volume":"559","author":"S Makin","year":"2018","unstructured":"Makin, S. The amyloid hypothesis on trial. Nature 559, S4\u2013S7 (2018).","journal-title":"Nature"},{"key":"1911_CR145","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","volume":"23","author":"GB Frisoni","year":"2022","unstructured":"Frisoni, G. B. et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat. Rev. Neurosci. 23, 53\u201366 (2022).","journal-title":"Nat. Rev. Neurosci."},{"key":"1911_CR146","doi-asserted-by":"publisher","first-page":"102161","DOI":"10.1016\/j.arr.2023.102161","volume":"93","author":"A Granzotto","year":"2024","unstructured":"Granzotto, A. & Sensi, S. L. Once upon a time, the Amyloid Cascade Hypothesis. Ageing Res. Rev. 93, 102161 (2024).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR147","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00401-018-1918-8","volume":"136","author":"GP Morris","year":"2018","unstructured":"Morris, G. P., Clark, I. A. & Vissel, B. Questions concerning the role of amyloid-beta in the definition, aetiology and diagnosis of Alzheimer\u2019s disease. Acta Neuropathol. 136, 663\u2013689 (2018).","journal-title":"Acta Neuropathol."},{"key":"1911_CR148","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jalz.2011.05.2408","volume":"8","author":"DJ Glass","year":"2012","unstructured":"Glass, D. J. & Arnold, S. E. Some evolutionary perspectives on Alzheimer\u2019s disease pathogenesis and pathology. Alzheimers Dement. 8, 343\u2013351 (2012).","journal-title":"Alzheimers Dement"},{"key":"1911_CR149","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.4103\/1673-5374.332127","volume":"17","author":"AR Roda","year":"2022","unstructured":"Roda, A. R. et al. Amyloid-beta peptide and tau protein crosstalk in Alzheimer\u2019s disease. Neural Regen. Res. 17, 1666\u20131674 (2022).","journal-title":"Neural Regen. Res."},{"key":"1911_CR150","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Interaction between A\u03b2 and Tau in the Pathogenesis of Alzheimer\u2019s Disease. Int J. Biol. Sci. 17, 2181\u20132192 (2021).","journal-title":"Int J. Biol. Sci."},{"key":"1911_CR151","doi-asserted-by":"publisher","first-page":"101126","DOI":"10.1016\/j.arr.2020.101126","volume":"64","author":"AC Bruni","year":"2020","unstructured":"Bruni, A. C., Bernardi, L. & Gabelli, C. From beta amyloid to altered proteostasis in Alzheimer\u2019s disease. Ageing Res. Rev. 64, 101126 (2020).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR152","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726\u2013734 (2022).","journal-title":"Lancet Neurol."},{"key":"1911_CR153","doi-asserted-by":"publisher","first-page":"9207","DOI":"10.3390\/ijms22179207","volume":"22","author":"J Sinsky","year":"2021","unstructured":"Sinsky, J., Pichlerova, K. & Hanes, J. Tau Protein Interaction Partners and Their Roles in Alzheimer\u2019s Disease and Other Tauopathies. Int J. Mol. Sci. 22, 9207 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR154","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s00415-021-10573-y","volume":"269","author":"Y Wei","year":"2022","unstructured":"Wei, Y., Liu, M. & Wang, D. The propagation mechanisms of extracellular tau in Alzheimer\u2019s disease. J. Neurol. 269, 1164\u20131181 (2022).","journal-title":"J. Neurol."},{"key":"1911_CR155","doi-asserted-by":"publisher","first-page":"106735","DOI":"10.1016\/j.bpc.2021.106735","volume":"281","author":"Y Tang","year":"2022","unstructured":"Tang, Y., Zhang, D., Gong, X. & Zheng, J. A mechanistic survey of Alzheimer\u2019s disease. Biophys. Chem. 281, 106735 (2022).","journal-title":"Biophys. Chem."},{"key":"1911_CR156","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10571-017-0574-1","volume":"38","author":"FP Chong","year":"2018","unstructured":"Chong, F. P., Ng, K. Y., Koh, R. Y. & Chye, S. M. Tau Proteins and Tauopathies in Alzheimer\u2019s Disease. Cell Mol. Neurobiol. 38, 965\u2013980 (2018).","journal-title":"Cell Mol. Neurobiol."},{"key":"1911_CR157","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1007\/s12035-019-1563-9","volume":"56","author":"G Bj\u00f8rklund","year":"2019","unstructured":"Bj\u00f8rklund, G., Aaseth, J., Dadar, M. & Chirumbolo, S. Molecular Targets in Alzheimer\u2019s Disease. Mol. Neurobiol. 56, 7032\u20137044 (2019).","journal-title":"Mol. Neurobiol."},{"key":"1911_CR158","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-180868","volume":"67","author":"H Almansoub","year":"2019","unstructured":"Almansoub, H. et al. Tau Abnormalities and the Potential Therapy in Alzheimer\u2019s Disease. J. Alzheimers Dis. 67, 13\u201333 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR159","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.4103\/0366-6999.220313","volume":"130","author":"XL Wu","year":"2017","unstructured":"Wu, X. L. et al. Tau-mediated Neurodegeneration and potential implications in diagnosis and treatment of Alzheimer\u2019s Disease. Chin. Med. J. 130, 2978\u20132990 (2017).","journal-title":"Chin. Med. J."},{"key":"1911_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.671779","volume":"14","author":"X Yin","year":"2021","unstructured":"Yin, X. et al. Dendritic\/Post-synaptic Tau and Early Pathology of Alzheimer\u2019s Disease. Front Mol. Neurosci. 14, 671779 (2021).","journal-title":"Front Mol. Neurosci."},{"key":"1911_CR161","doi-asserted-by":"publisher","first-page":"165584","DOI":"10.1016\/j.bbadis.2019.165584","volume":"1866","author":"G Amadoro","year":"2020","unstructured":"Amadoro, G., Latina, V., Corsetti, V. & Calissano, P. N-terminal tau truncation in the pathogenesis of Alzheimer\u2019s disease (AD): Developing a novel diagnostic and therapeutic approach. Biochim Biophys. Acta Mol. Basis Dis. 1866, 165584 (2020).","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"1911_CR162","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/j.1460-2075.1993.tb05665.x","volume":"12","author":"M Novak","year":"1993","unstructured":"Novak, M., Kabat, J. & Wischik, C. M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer\u2019s disease paired helical filament. EMBO J. 12, 365\u2013370 (1993).","journal-title":"EMBO J."},{"key":"1911_CR163","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm0896-871","volume":"2","author":"JZ Wang","year":"1996","unstructured":"Wang, J. Z., Grundke-Iqbal, I. & Iqbal, K. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer\u2019s disease. Nat. Med. 2, 871\u2013875 (1996).","journal-title":"Nat. Med."},{"key":"1911_CR164","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bbadis.2015.12.002","volume":"1862","author":"K Liu","year":"2016","unstructured":"Liu, K. et al. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property. Biochim. Biophys. Acta 1862, 192\u2013201 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"1911_CR165","doi-asserted-by":"publisher","first-page":"16586","DOI":"10.1073\/pnas.1417548111","volume":"111","author":"HB Luo","year":"2014","unstructured":"Luo, H. B. et al. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc. Natl Acad. Sci. USA 111, 16586\u201316591 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1911_CR166","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-med-052919-120219","volume":"72","author":"WJ Ray","year":"2021","unstructured":"Ray, W. J. & Buggia-Prevot, V. Novel Targets for Alzheimer\u2019s Disease: A View Beyond Amyloid. Annu. Rev. Med. 72, 15\u201328 (2021).","journal-title":"Annu. Rev. Med."},{"key":"1911_CR167","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1002\/alz.13396","volume":"19","author":"I Sintini","year":"2023","unstructured":"Sintini, I. et al. Longitudinal rates of atrophy and tau accumulation differ between the visual and language variants of atypical Alzheimer\u2019s disease. Alzheimers Dement. 19, 4396\u20134406 (2023).","journal-title":"Alzheimers Dement."},{"key":"1911_CR168","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jalz.2018.02.020","volume":"14","author":"JL Whitwell","year":"2018","unstructured":"Whitwell, J. L. et al. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer\u2019s disease. Alzheimers Dement. 14, 1005\u20131014 (2018).","journal-title":"Alzheimers Dement."},{"key":"1911_CR169","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1002\/alz.13011","volume":"19","author":"PSJ Weston","year":"2023","unstructured":"Weston, P. S. J. et al. Cortical tau is associated with microstructural imaging biomarkers of neurite density and dendritic complexity in Alzheimer\u2019s disease. Alzheimers Dement. 19, 2750\u20132754 (2023).","journal-title":"Alzheimers Dement."},{"key":"1911_CR170","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev-neuro-070815-014015","volume":"39","author":"C Sala Frigerio","year":"2016","unstructured":"Sala Frigerio, C. & De Strooper, B. Alzheimer\u2019s Disease Mechanisms and Emerging Roads to Novel Therapeutics. Annu. Rev. Neurosci. 39, 57\u201379 (2016).","journal-title":"Annu. Rev. Neurosci."},{"key":"1911_CR171","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. 17, 157\u2013172 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1911_CR172","doi-asserted-by":"crossref","unstructured":"von Bernhardi, R., Eugen\u00edn-von Bernhardi, L. & Eugen\u00edn, J. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci. 7, 124 (2015).","DOI":"10.3389\/fnagi.2015.00124"},{"key":"1911_CR173","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.phrs.2018.01.017","volume":"130","author":"C Balducci","year":"2018","unstructured":"Balducci, C. & Forloni, G. Novel targets in Alzheimer\u2019s disease: A special focus on microglia. Pharm. Res. 130, 402\u2013413 (2018).","journal-title":"Pharm. Res."},{"key":"1911_CR174","doi-asserted-by":"publisher","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","volume":"28","author":"SE Hickman","year":"2008","unstructured":"Hickman, S. E., Allison, E. K. & El Khoury, J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer\u2019s disease mice. J. Neurosci. 28, 8354\u20138360 (2008).","journal-title":"J. Neurosci."},{"key":"1911_CR175","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1152\/physrev.00015.2020","volume":"101","author":"C Ferrari","year":"2021","unstructured":"Ferrari, C. & Sorbi, S. The complexity of Alzheimer\u2019s disease: an evolving puzzle. Physiol. Rev. 101, 1047\u20131081 (2021).","journal-title":"Physiol. Rev."},{"key":"1911_CR176","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas, C. et al. Microglia-derived ASC specks cross-seed amyloid-\u03b2 in Alzheimer\u2019s disease. Nature 552, 355\u2013361 (2017).","journal-title":"Nature"},{"key":"1911_CR177","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche, M. A. & Hyman, B. T. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat. Neurosci. 23, 1183\u20131193 (2020).","journal-title":"Nat. Neurosci."},{"key":"1911_CR178","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fnagi.2019.00271","volume":"11","author":"E \u0160pani\u0107","year":"2019","unstructured":"\u0160pani\u0107, E., Langer Horvat, L., Hof, P. R. & \u0160imi\u0107, G. Role of Microglial Cells in Alzheimer\u2019s Disease Tau Propagation. Front. Aging Neurosci. 11, 271 (2019).","journal-title":"Front. Aging Neurosci."},{"key":"1911_CR179","doi-asserted-by":"publisher","first-page":"6052932","DOI":"10.1155\/2022\/6052932","volume":"2022","author":"DM Sumsuzzman","year":"2022","unstructured":"Sumsuzzman, D. M. et al. Microglia in Alzheimer\u2019s Disease: A Favorable Cellular Target to Ameliorate Alzheimer\u2019s Pathogenesis. Mediators Inflamm. 2022, 6052932 (2022).","journal-title":"Mediators Inflamm."},{"key":"1911_CR180","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.3390\/molecules27134124","volume":"27","author":"ZM Althafar","year":"2022","unstructured":"Althafar, Z. M. Targeting Microglia in Alzheimer\u2019s Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules. Molecules 27, 4124 (2022).","journal-title":"Molecules"},{"key":"1911_CR181","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neuron.2022.12.032","volume":"111","author":"MT Heneka","year":"2023","unstructured":"Heneka, M. T. ApoE4 makes microglia trem(2)bling. Neuron 111, 142\u2013144 (2023).","journal-title":"Neuron"},{"key":"1911_CR182","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","volume":"15","author":"T Guo","year":"2020","unstructured":"Guo, T. et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease. Mol. Neurodegener. 15, 40 (2020).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR183","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41590-023-01640-9","volume":"24","author":"CC Liu","year":"2023","unstructured":"Liu, C. C. et al. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer\u2019s disease. Nat. Immunol. 24, 1854\u20131866 (2023).","journal-title":"Nat. Immunol."},{"key":"1911_CR184","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","volume":"29","author":"WK Self","year":"2023","unstructured":"Self, W. K. & Holtzman, D. M. Emerging diagnostics and therapeutics for Alzheimer disease. Nat. Med. 29, 2187\u20132199 (2023).","journal-title":"Nat. Med."},{"key":"1911_CR185","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang, W., Xiao, D., Mao, Q. & Xia, H. Role of neuroinflammation in neurodegeneration development. Signal Transduct. Target Ther. 8, 267 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR186","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3121\/cmr.2023.1841","volume":"21","author":"A Nouraeinejad","year":"2023","unstructured":"Nouraeinejad, A. The Link Between COVID-19 and Alzheimer Disease Through Neuroinflammation. Clin. Med. Res. 21, 119\u2013121 (2023).","journal-title":"Clin. Med. Res."},{"key":"1911_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122132","volume":"333","author":"L Bello-Corral","year":"2023","unstructured":"Bello-Corral, L. et al. Implications of gut and oral microbiota in neuroinflammatory responses in Alzheimer\u2019s disease. Life Sci. 333, 122132 (2023).","journal-title":"Life Sci."},{"key":"1911_CR188","doi-asserted-by":"publisher","first-page":"1161850","DOI":"10.3389\/fphar.2023.1161850","volume":"14","author":"M Wong-Guerra","year":"2023","unstructured":"Wong-Guerra, M., Calfio, C., Maccioni, R. B. & Rojo, L. E. Revisiting the neuroinflammation hypothesis in Alzheimer\u2019s disease: a focus on the druggability of current targets. Front. Pharm. 14, 1161850 (2023).","journal-title":"Front. Pharm."},{"key":"1911_CR189","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro, V. & Edison, P. Neuroinflammation in Alzheimer\u2019s disease: Current evidence and future directions. Alzheimers Dement. 12, 719\u2013732 (2016).","journal-title":"Alzheimers Dement."},{"key":"1911_CR190","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/alz.12610","volume":"18","author":"D Lecca","year":"2022","unstructured":"Lecca, D. et al. Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. Alzheimers Dement. 18, 2327\u20132340 (2022).","journal-title":"Alzheimers Dement."},{"key":"1911_CR191","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.tips.2008.09.001","volume":"29","author":"D Pratic\u00f2","year":"2008","unstructured":"Pratic\u00f2, D. Oxidative stress hypothesis in Alzheimer\u2019s disease: a reappraisal. Trends Pharm. Sci. 29, 609\u2013615 (2008).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR192","doi-asserted-by":"publisher","first-page":"621S","DOI":"10.1093\/ajcn\/71.2.621s","volume":"71","author":"Y Christen","year":"2000","unstructured":"Christen, Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71, 621S\u2013629S (2000).","journal-title":"Am. J. Clin. Nutr."},{"key":"1911_CR193","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0891-5849(96)00629-6","volume":"23","author":"WR Markesbery","year":"1997","unstructured":"Markesbery, W. R. Oxidative stress hypothesis in Alzheimer\u2019s disease. Free Radic. Biol. Med. 23, 134\u2013147 (1997).","journal-title":"Free Radic. Biol. Med."},{"key":"1911_CR194","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0301-0082(00)00015-0","volume":"62","author":"S Miranda","year":"2000","unstructured":"Miranda, S. et al. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer\u2019s disease. Prog. Neurobiol. 62, 633\u2013648 (2000).","journal-title":"Prog. Neurobiol."},{"key":"1911_CR195","doi-asserted-by":"publisher","first-page":"101619","DOI":"10.1016\/j.arr.2022.101619","volume":"77","author":"R Bai","year":"2022","unstructured":"Bai, R. et al. Oxidative stress: The core pathogenesis and mechanism of Alzheimer\u2019s disease. Ageing Res. Rev. 77, 101619 (2022).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR196","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12264-013-1423-y","volume":"30","author":"Z Chen","year":"2014","unstructured":"Chen, Z. & Zhong, C. Oxidative stress in Alzheimer\u2019s disease. Neurosci. Bull. 30, 271\u2013281 (2014).","journal-title":"Neurosci. Bull."},{"key":"1911_CR197","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1021\/jm400970m","volume":"57","author":"M Rosini","year":"2014","unstructured":"Rosini, M. et al. Oxidative stress in Alzheimer\u2019s disease: are we connecting the dots? J. Med. Chem. 57, 2821\u20132831 (2014).","journal-title":"J. Med. Chem."},{"key":"1911_CR198","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10571-015-0157-y","volume":"35","author":"ME Ferreira","year":"2015","unstructured":"Ferreira, M. E. et al. Oxidative Stress in Alzheimer\u2019s Disease: Should We Keep Trying Antioxidant Therapies? Cell Mol. Neurobiol. 35, 595\u2013614 (2015).","journal-title":"Cell Mol. Neurobiol."},{"key":"1911_CR199","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.tips.2017.04.005","volume":"38","author":"P Poprac","year":"2017","unstructured":"Poprac, P. et al. Targeting Free Radicals in Oxidative Stress-Related Human Diseases. Trends Pharm. Sci. 38, 592\u2013607 (2017).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR200","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1152\/physrev.00030.2022","volume":"104","author":"M Perluigi","year":"2024","unstructured":"Perluigi, M., Di Domenico, F. & Butterfield, D. A. Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease. Physiol. Rev. 104, 103\u2013197 (2024).","journal-title":"Physiol. Rev."},{"key":"1911_CR201","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1021\/acschemneuro.3c00486","volume":"14","author":"RG Roy","year":"2023","unstructured":"Roy, R. G., Mandal, P. K. & Maroon, J. C. Oxidative Stress Occurs Prior to Amyloid A\u03b2 Plaque Formation and Tau Phosphorylation in Alzheimer\u2019s Disease: Role of Glutathione and Metal Ions. ACS Chem. Neurosci. 14, 2944\u20132954 (2023).","journal-title":"ACS Chem. Neurosci."},{"key":"1911_CR202","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.freeradbiomed.2021.08.019","volume":"179","author":"OD Sanders","year":"2022","unstructured":"Sanders, O. D., Rajagopal, L. & Rajagopal, J. A. The oxidatively damaged DNA and amyloid-\u03b2 oligomer hypothesis of Alzheimer\u2019s disease. Free Radic. Biol. Med. 179, 403\u2013412 (2022).","journal-title":"Free Radic. Biol. Med."},{"key":"1911_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106301","volume":"131","author":"LL Chen","year":"2023","unstructured":"Chen, L. L. et al. The metal ion hypothesis of Alzheimer\u2019s disease and the anti-neuroinflammatory effect of metal chelators. Bioorg. Chem. 131, 106301 (2023).","journal-title":"Bioorg. Chem."},{"key":"1911_CR204","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.freeradbiomed.2012.10.558","volume":"62","author":"S Ayton","year":"2013","unstructured":"Ayton, S., Lei, P. & Bush, A. I. Metallostasis in Alzheimer\u2019s disease. Free Radic. Biol. Med. 62, 76\u201389 (2013).","journal-title":"Free Radic. Biol. Med."},{"key":"1911_CR205","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.tips.2018.10.001","volume":"39","author":"SL Sensi","year":"2018","unstructured":"Sensi, S. L., Granzotto, A., Siotto, M. & Squitti, R. Copper and Zinc Dysregulation in Alzheimer\u2019s Disease. Trends Pharm. Sci. 39, 1049\u20131063 (2018).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR206","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejmech.2018.02.084","volume":"150","author":"CW D\u2019Acunto","year":"2018","unstructured":"D\u2019Acunto, C. W. et al. Metallomics for Alzheimer\u2019s disease treatment: Use of new generation of chelators combining metal-cation binding and transport properties. Eur. J. Med. Chem. 150, 140\u2013155 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2017.12.001","volume":"38","author":"F Caraci","year":"2018","unstructured":"Caraci, F., Nicoletti, F. & Copani, A. Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer\u2019s disease. Curr. Opin. Pharm. 38, 1\u20137 (2018).","journal-title":"Curr. Opin. Pharm."},{"key":"1911_CR208","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pneurobio.2018.12.006","volume":"174","author":"P Sharma","year":"2019","unstructured":"Sharma, P. et al. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer\u2019s disease and potential therapeutic strategies. Prog. Neurobiol. 174, 53\u201389 (2019).","journal-title":"Prog. Neurobiol."},{"key":"1911_CR209","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/alz.12398","volume":"18","author":"W Zhong","year":"2022","unstructured":"Zhong, W. et al. Pathogenesis of sporadic Alzheimer\u2019s disease by deficiency of NMDA receptor subunit GluN3A. Alzheimers Dement. 18, 222\u2013239 (2022).","journal-title":"Alzheimers Dement."},{"key":"1911_CR210","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40035-021-00278-7","volume":"11","author":"M Verma","year":"2022","unstructured":"Verma, M., Lizama, B. N. & Chu, C. T. Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Transl. Neurodegener. 11, 3 (2022).","journal-title":"Transl. Neurodegener."},{"key":"1911_CR211","doi-asserted-by":"publisher","first-page":"600089","DOI":"10.3389\/fnmol.2020.600089","volume":"13","author":"A Granzotto","year":"2020","unstructured":"Granzotto, A., Canzoniero, L. M. T. & Sensi, S. L. A Neurotoxic M\u00e9nage-\u00e0-trois: Glutamate, Calcium, and Zinc in the Excitotoxic Cascade. Front. Mol. Neurosci. 13, 600089 (2020).","journal-title":"Front. Mol. Neurosci."},{"key":"1911_CR212","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/alz.12088","volume":"16","author":"D Bi","year":"2020","unstructured":"Bi, D., Wen, L., Wu, Z. & Shen, Y. GABAergic dysfunction in excitatory and inhibitory (E\/I) imbalance drives the pathogenesis of Alzheimer\u2019s disease. Alzheimers Dement. 16, 1312\u20131329 (2020).","journal-title":"Alzheimers Dement."},{"key":"1911_CR213","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1007\/s12035-020-02073-3","volume":"57","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. Gut Microbiota and Dysbiosis in Alzheimer\u2019s Disease: Implications for Pathogenesis and Treatment. Mol. Neurobiol. 57, 5026\u20135043 (2020).","journal-title":"Mol. Neurobiol."},{"key":"1911_CR214","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13024-020-00378-4","volume":"15","author":"HR Bulgart","year":"2020","unstructured":"Bulgart, H. R., Neczypor, E. W., Wold, L. E. & Mackos, A. R. Microbial involvement in Alzheimer disease development and progression. Mol. Neurodegener. 15, 42 (2020).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR215","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/nu10091267","volume":"10","author":"F La Rosa","year":"2018","unstructured":"La Rosa, F. et al. The Gut-Brain Axis in Alzheimer\u2019s Disease and Omega-3. A Critical Overview of Clinical Trials. Nutrients 10, 1267 (2018).","journal-title":"Nutrients"},{"key":"1911_CR216","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s11427-016-5083-9","volume":"59","author":"X Hu","year":"2016","unstructured":"Hu, X., Wang, T. & Jin, F. Alzheimer\u2019s disease and gut microbiota. Sci. China Life Sci. 59, 1006\u20131023 (2016).","journal-title":"Sci. China Life Sci."},{"key":"1911_CR217","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s12035-018-1188-4","volume":"56","author":"M Sochocka","year":"2019","unstructured":"Sochocka, M. et al. The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer\u2019s Disease-a Critical Review. Mol. Neurobiol. 56, 1841\u20131851 (2019).","journal-title":"Mol. Neurobiol."},{"key":"1911_CR218","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/nu13010037","volume":"13","author":"A Megur","year":"2020","unstructured":"Megur, A., Baltriukien\u0117, D., Bukelskien\u0117, V. & Burokas, A. The Microbiota-Gut-Brain Axis and Alzheimer\u2019s Disease: Neuroinflammation Is to Blame? Nutrients 13, 37 (2020).","journal-title":"Nutrients"},{"key":"1911_CR219","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo2984","volume":"15","author":"AL Ferreiro","year":"2023","unstructured":"Ferreiro, A. L. et al. Gut microbiome composition may be an indicator of preclinical Alzheimer\u2019s disease. Sci. Transl. Med. 15, eabo2984 (2023).","journal-title":"Sci. Transl. Med"},{"key":"1911_CR220","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.24272\/j.issn.2095-8137.2023.294","volume":"44","author":"X-W Zhang","year":"2023","unstructured":"Zhang, X.-W., Zhu, X.-X., Tang, D.-S. & Lu, J.-H. Targeting autophagy in Alzheimer\u2019s disease: Animal models and mechanisms. Zool. Res. 44, 1132\u20131145 (2023).","journal-title":"Zool. Res."},{"key":"1911_CR221","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s43587-021-00098-4","volume":"1","author":"Y Aman","year":"2021","unstructured":"Aman, Y. et al. Autophagy in healthy aging and disease. Nat. Aging 1, 634\u2013650 (2021).","journal-title":"Nat. Aging"},{"key":"1911_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108171","volume":"237","author":"M Eshraghi","year":"2022","unstructured":"Eshraghi, M. et al. Enhancing autophagy in Alzheimer\u2019s disease through drug repositioning. Pharm. Ther. 237, 108171 (2022).","journal-title":"Pharm. Ther."},{"key":"1911_CR223","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41580-018-0001-6","volume":"19","author":"S Kaushik","year":"2018","unstructured":"Kaushik, S. & Cuervo, A. M. The coming of age of chaperone-mediated autophagy. Nat. Rev. Mol. Cell Biol. 19, 365\u2013381 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1911_CR224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2020.1797280","volume":"17","author":"DJ Klionsky","year":"2021","unstructured":"Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). Autophagy 17, 1\u2013382 (2021).","journal-title":"Autophagy"},{"key":"1911_CR225","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.bbadis.2008.10.002","volume":"1782","author":"NB Nedelsky","year":"2008","unstructured":"Nedelsky, N. B., Todd, P. K. & Taylor, J. P. Autophagy and the ubiquitin-proteasome system: Collaborators in neuroprotection. Biochim Biophys. Acta 1782, 691\u2013699 (2008).","journal-title":"Biochim Biophys. Acta"},{"key":"1911_CR226","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/cells8010004","volume":"8","author":"Z Dong","year":"2018","unstructured":"Dong, Z. & Cui, H. The Autophagy-Lysosomal Pathways and Their Emerging Roles in Modulating Proteostasis in Tumors. Cells 8, 4 (2018).","journal-title":"Cells"},{"key":"1911_CR227","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.apsb.2021.12.009","volume":"12","author":"Z Deng","year":"2022","unstructured":"Deng, Z. et al. Pharmacological modulation of autophagy for Alzheimer\u2019s disease therapy: Opportunities and obstacles. Acta Pharm. Sin. B 12, 1688\u20131706 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1911_CR228","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1017\/erm.2015.19","volume":"18","author":"M Iranpour","year":"2016","unstructured":"Iranpour, M. et al. Apoptosis, autophagy and unfolded protein response pathways in Arbovirus replication and pathogenesis. Expert Rev. Mol. Med. 18, e1 (2016).","journal-title":"Expert Rev. Mol. Med."},{"key":"1911_CR229","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nm.3232","volume":"19","author":"RA Nixon","year":"2013","unstructured":"Nixon, R. A. The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983\u2013997 (2013).","journal-title":"Nat. Med."},{"key":"1911_CR230","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1083\/jcb.200505082","volume":"171","author":"WH Yu","year":"2005","unstructured":"Yu, W. H. et al. Macroautophagy\u2014a novel \u03b2-amyloid peptide-generating pathway activated in Alzheimer\u2019s disease. J. Cell Biol. 171, 87\u201398 (2005).","journal-title":"J. Cell Biol."},{"key":"1911_CR231","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.tins.2017.01.002","volume":"40","author":"JS Kerr","year":"2017","unstructured":"Kerr, J. S. et al. Mitophagy and Alzheimer\u2019s Disease: Cellular and Molecular Mechanisms. Trends Neurosci. 40, 151\u2013166 (2017).","journal-title":"Trends Neurosci."},{"key":"1911_CR232","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1016\/j.cell.2021.03.048","volume":"184","author":"M Bourdenx","year":"2021","unstructured":"Bourdenx, M. et al. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell 184, 2696\u20132714.e2625 (2021).","journal-title":"Cell"},{"key":"1911_CR233","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1065183","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Microglial autophagy in Alzheimer\u2019s disease and Parkinson\u2019s disease. Front. Aging Neurosci. 14, 1065183 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"1911_CR234","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1038\/s41380-023-02242-5","volume":"28","author":"A Litwiniuk","year":"2023","unstructured":"Litwiniuk, A., Juszczak, G. R., Stankiewicz, A. M. & Urba\u0144ska, K. The role of glial autophagy in Alzheimer\u2019s disease. Mol. Psychiatry 28, 4528\u20134539 (2023).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR235","doi-asserted-by":"publisher","first-page":"101464","DOI":"10.1016\/j.arr.2021.101464","volume":"72","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z., Yang, X., Song, Y.-Q. & Tu, J. Autophagy in Alzheimer\u2019s disease pathogenesis: Therapeutic potential and future perspectives. Ageing Res. Rev. 72, 101464 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR236","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/ADR-190104","volume":"3","author":"S Chandra","year":"2019","unstructured":"Chandra, S. & Pahan, K. Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimer\u2019s Disease via Peroxisome Proliferator-Activated Receptor \u03b1. J. Alzheimers Dis. Rep. 3, 149\u2013168 (2019).","journal-title":"J. Alzheimers Dis. Rep."},{"key":"1911_CR237","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/15548627.2019.1596488","volume":"16","author":"R Luo","year":"2020","unstructured":"Luo, R. et al. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy 16, 52\u201369 (2020).","journal-title":"Autophagy"},{"key":"1911_CR238","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/ijmm.2023.5314","volume":"52","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y. et al. Inflammatory signaling pathways in the treatment of Alzheimer\u2019s disease with inhibitors, natural products and metabolites (Review). Int. J. Mol. Med. 52, 111 (2023).","journal-title":"Int. J. Mol. Med."},{"key":"1911_CR239","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur, S. et al. Neuroinflammation in Alzheimer\u2019s Disease: Current Progress in Molecular Signaling and Therapeutics. Inflammation 46, 1\u201317 (2023).","journal-title":"Inflammation"},{"key":"1911_CR240","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s10787-021-00889-6","volume":"29","author":"R Dhapola","year":"2021","unstructured":"Dhapola, R. et al. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer\u2019s disease. Inflammopharmacology 29, 1669\u20131681 (2021).","journal-title":"Inflammopharmacology"},{"key":"1911_CR241","doi-asserted-by":"publisher","first-page":"115817","DOI":"10.1016\/j.ejmech.2023.115817","volume":"261","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Targeting protein kinases for the treatment of Alzheimer\u2019s disease: Recent progress and future perspectives. Eur. J. Med. Chem. 261, 115817 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR242","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1080\/10408398.2021.1975093","volume":"63","author":"R Huang","year":"2023","unstructured":"Huang, R. et al. Whole-plant foods and their macromolecules: untapped approaches to modulate neuroinflammation in Alzheimer\u2019s disease. Crit. Rev. Food Sci. Nutr. 63, 2388\u20132406 (2023).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"1911_CR243","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.phrs.2017.11.030","volume":"129","author":"E-J Seo","year":"2018","unstructured":"Seo, E.-J., Fischer, N. & Efferth, T. J. P. Phytochemicals as inhibitors of NF-\u03baB for treatment of Alzheimer\u2019s disease. Pharm. Res. 129, 262\u2013273 (2018).","journal-title":"Pharm. Res."},{"key":"1911_CR244","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cr.2010.178","volume":"21","author":"MJ Morgan","year":"2011","unstructured":"Morgan, M. J. & Liu, Z. G. Crosstalk of reactive oxygen species and NF-\u03baB signaling. Cell Res. 21, 103\u2013115 (2011).","journal-title":"Cell Res."},{"key":"1911_CR245","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bbi.2024.02.016","volume":"118","author":"K Zhao","year":"2024","unstructured":"Zhao, K. et al. The miR-25802\/KLF4\/NF-\u03baB signaling axis regulates microglia-mediated neuroinflammation in Alzheimer\u2019s disease. Brain Behav. Immun. 118, 31\u201348 (2024).","journal-title":"Brain Behav. Immun."},{"key":"1911_CR246","doi-asserted-by":"publisher","first-page":"879021","DOI":"10.3389\/fnagi.2022.879021","volume":"14","author":"HM Blevins","year":"2022","unstructured":"Blevins, H. M., Xu, Y., Biby, S. & Zhang, S. The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases. Front Aging Neurosci. 14, 879021 (2022).","journal-title":"Front Aging Neurosci."},{"key":"1911_CR247","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbi.2023.11.031","volume":"116","author":"A Naeem","year":"2024","unstructured":"Naeem, A. et al. MCC950 reduces autophagy and improves cognitive function by inhibiting NLRP3-dependent neuroinflammation in a rat model of Alzheimer\u2019s disease. Brain Behav. Immun. 116, 70\u201384 (2024).","journal-title":"Brain Behav. Immun."},{"key":"1911_CR248","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13024-023-00674-9","volume":"18","author":"G Terzioglu","year":"2023","unstructured":"Terzioglu, G. & Young-Pearse, T. L. Microglial function, INPP5D\/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer\u2019s disease. Mol. Neurodegener. 18, 89 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR249","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00401-022-02528-y","volume":"145","author":"S Moonen","year":"2023","unstructured":"Moonen, S. et al. Pyroptosis in Alzheimer\u2019s disease: cell type-specific activation in microglia, astrocytes and neurons. Acta Neuropathol. 145, 175\u2013195 (2023).","journal-title":"Acta Neuropathol."},{"key":"1911_CR250","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29552-6","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang, C. et al. Microglial NF-\u03baB drives tau spreading and toxicity in a mouse model of tauopathy. Nat. Commun. 13, 1969 (2022).","journal-title":"Nat. Commun."},{"key":"1911_CR251","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161987","volume":"133","author":"D Dutta","year":"2023","unstructured":"Dutta, D. et al. Tau fibrils induce glial inflammation and neuropathology via TLR2 in Alzheimer\u2019s disease-related mouse models. J. Clin. Invest. 133, e161987 (2023).","journal-title":"J. Clin. Invest."},{"key":"1911_CR252","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising, C. et al. NLRP3 inflammasome activation drives tau pathology. Nature 575, 669\u2013673 (2019).","journal-title":"Nature"},{"key":"1911_CR253","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s43587-022-00337-2","volume":"3","author":"X Xie","year":"2023","unstructured":"Xie, X. et al. Activation of innate immune cGAS-STING pathway contributes to Alzheimer\u2019s pathogenesis in 5\u00d7FAD mice. Nat. Aging 3, 202\u2013212 (2023).","journal-title":"Nat. Aging"},{"key":"1911_CR254","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13024-023-00672-x","volume":"18","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders. Mol. Neurodegener. 18, 79 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR255","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01155-w","volume":"15","author":"M Jorfi","year":"2023","unstructured":"Jorfi, M., Maaser-Hecker, A. & Tanzi, R. E. The neuroimmune axis of Alzheimer\u2019s disease. Genome Med. 15, 6 (2023).","journal-title":"Genome Med."},{"key":"1911_CR256","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1453-0","volume":"16","author":"DA Dionisio-Santos","year":"2019","unstructured":"Dionisio-Santos, D. A., Olschowka, J. A. & O\u2019Banion, M. K. Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer\u2019s disease. J. Neuroinflamm. 16, 74 (2019).","journal-title":"J. Neuroinflamm."},{"key":"1911_CR257","doi-asserted-by":"crossref","unstructured":"Jorfi, M. et al. Infiltrating CD8+ T cells exacerbate Alzheimer\u2019s disease pathology in a 3D human neuroimmune axis model. Nat. Neurosci. 26, 1489\u20131504 (2023).","DOI":"10.1038\/s41593-023-01415-3"},{"key":"1911_CR258","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bbi.2020.05.070","volume":"89","author":"MS Unger","year":"2020","unstructured":"Unger, M. S. et al. CD8(+) T-cells infiltrate Alzheimer\u2019s disease brains and regulate neuronal- and synapse-related gene expression in APP-PS1 transgenic mice. Brain Behav. Immun. 89, 67\u201386 (2020).","journal-title":"Brain Behav. Immun."},{"key":"1911_CR259","doi-asserted-by":"publisher","first-page":"20862","DOI":"10.18632\/aging.104104","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. TREM2 ameliorates neuroinflammatory response and cognitive impairment via PI3K\/AKT\/FoxO3a signaling pathway in Alzheimer\u2019s disease mice. Aging 12, 20862\u201320879 (2020).","journal-title":"Aging"},{"key":"1911_CR260","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.immuni.2023.06.016","volume":"56","author":"L Zhong","year":"2023","unstructured":"Zhong, L. et al. TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration. Immunity 56, 1794\u20131808.e8 (2023).","journal-title":"Immunity"},{"key":"1911_CR261","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41392-021-00778-y","volume":"6","author":"M Cao","year":"2021","unstructured":"Cao, M., Luo, X., Wu, K. & He, X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct. Target Ther. 6, 379 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR262","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40035-015-0041-1","volume":"4","author":"YB Hu","year":"2015","unstructured":"Hu, Y. B., Dammer, E. B., Ren, R. J. & Wang, G. The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration. Transl. Neurodegener. 4, 18 (2015).","journal-title":"Transl. Neurodegener."},{"key":"1911_CR263","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/alzrt217","volume":"5","author":"ME Orr","year":"2013","unstructured":"Orr, M. E. & Oddo, S. Autophagic\/lysosomal dysfunction in Alzheimer\u2019s disease. Alzheimers Res. Ther. 5, 53 (2013).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR264","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s11427-016-5090-x","volume":"59","author":"J Xiong","year":"2016","unstructured":"Xiong, J. & Zhu, M. X. Regulation of lysosomal ion homeostasis by channels and transporters. Sci. China Life Sci. 59, 777\u2013791 (2016).","journal-title":"Sci. China Life Sci."},{"key":"1911_CR265","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40035-023-00362-0","volume":"12","author":"CH Lo","year":"2023","unstructured":"Lo, C. H. & Zeng, J. Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases. Transl. Neurodegener. 12, 29 (2023).","journal-title":"Transl. Neurodegener."},{"key":"1911_CR266","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.cell.2010.05.008","volume":"141","author":"JH Lee","year":"2010","unstructured":"Lee, J. H. et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146\u20131158 (2010).","journal-title":"Cell"},{"key":"1911_CR267","doi-asserted-by":"publisher","first-page":"8633","DOI":"10.1523\/JNEUROSCI.0556-12.2012","volume":"32","author":"X Zhang","year":"2012","unstructured":"Zhang, X. et al. A role for presenilins in autophagy revisited: normal acidification of lysosomes in cells lacking PSEN1 and PSEN2. J. Neurosci. 32, 8633\u20138648 (2012).","journal-title":"J. Neurosci."},{"key":"1911_CR268","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1083\/jcb.201201076","volume":"198","author":"K Coen","year":"2012","unstructured":"Coen, K. et al. Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells. J. Cell Biol. 198, 23\u201335 (2012).","journal-title":"J. Cell Biol."},{"key":"1911_CR269","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.celrep.2015.07.050","volume":"12","author":"JH Lee","year":"2015","unstructured":"Lee, J. H. et al. Presenilin 1 Maintains Lysosomal Ca(2+) Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. Cell Rep. 12, 1430\u20131444 (2015).","journal-title":"Cell Rep."},{"key":"1911_CR270","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1080\/15548627.2021.1945220","volume":"18","author":"BC Tong","year":"2022","unstructured":"Tong, B. C. et al. Lysosomal TPCN (two pore segment channel) inhibition ameliorates beta-amyloid pathology and mitigates memory impairment in Alzheimer disease. Autophagy 18, 624\u2013642 (2022).","journal-title":"Autophagy"},{"key":"1911_CR271","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg1925","volume":"9","author":"E Im","year":"2023","unstructured":"Im, E. et al. Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr(682)-phosphorylated APP \u03b2CTF. Sci. Adv. 9, eadg1925 (2023).","journal-title":"Sci. Adv."},{"key":"1911_CR272","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00041433-200104000-00003","volume":"12","author":"JM Dietschy","year":"2001","unstructured":"Dietschy, J. M. & Turley, S. D. Cholesterol metabolism in the brain. Curr. Opin. Lipido 12, 105\u2013112 (2001).","journal-title":"Curr. Opin. Lipido"},{"key":"1911_CR273","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/brain\/awae028","volume":"147","author":"H Ahmed","year":"2024","unstructured":"Ahmed, H. et al. Brain cholesterol and Alzheimer\u2019s disease: challenges and opportunities in probe and drug development. Brain 147, 1622\u20131635 (2024).","journal-title":"Brain"},{"key":"1911_CR274","doi-asserted-by":"publisher","first-page":"1","DOI":"10.37349\/ent.2022.00015","volume":"2","author":"L Qian","year":"2022","unstructured":"Qian, L., Chai, A. B., Gelissen, I. C. & Brown, A. J. J. Eo. N. T. Balancing cholesterol in the brain: From synthesis to disposal. Explor Neuroprot. Ther. 2, 1\u201327 (2022).","journal-title":"Explor Neuroprot. Ther."},{"key":"1911_CR275","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tins.2022.01.002","volume":"45","author":"D Li","year":"2022","unstructured":"Li, D., Zhang, J. & Liu, Q. Brain cell type-specific cholesterol metabolism and implications for learning and memory. Trends Neurosci. 45, 401\u2013414 (2022).","journal-title":"Trends Neurosci."},{"key":"1911_CR276","doi-asserted-by":"publisher","first-page":"690372","DOI":"10.3389\/fnagi.2021.690372","volume":"13","author":"FM Feringa","year":"2021","unstructured":"Feringa, F. M. & van der Kant, R. Cholesterol and Alzheimer\u2019s Disease; From Risk Genes to Pathological Effects. Front Aging Neurosci. 13, 690372 (2021).","journal-title":"Front Aging Neurosci."},{"key":"1911_CR277","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0896-6273(03)00840-7","volume":"41","author":"B Wolozin","year":"2004","unstructured":"Wolozin, B. Cholesterol and the biology of Alzheimer\u2019s disease. Neuron 41, 7\u201310 (2004).","journal-title":"Neuron"},{"key":"1911_CR278","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102191118","volume":"118","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proc. Natl Acad. Sci. USA 118, e2102191118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1911_CR279","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-022-01006-x","volume":"7","author":"S Huang","year":"2022","unstructured":"Huang, S. et al. Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer\u2019s tau pathology. Signal Transduct. Target Ther. 7, 176 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR280","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.neuron.2023.10.023","volume":"112","author":"A Litvinchuk","year":"2024","unstructured":"Litvinchuk, A. et al. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron 112, 384\u2013403.e8 (2024).","journal-title":"Neuron"},{"key":"1911_CR281","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40035-023-00343-3","volume":"12","author":"C de Dios","year":"2023","unstructured":"de Dios, C. et al. Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis. Transl. Neurodegener. 12, 10 (2023).","journal-title":"Transl. Neurodegener."},{"key":"1911_CR282","doi-asserted-by":"publisher","first-page":"101529","DOI":"10.1016\/j.arr.2021.101529","volume":"73","author":"P Gowda","year":"2022","unstructured":"Gowda, P., Reddy, P. H. & Kumar, S. Deregulated mitochondrial microRNAs in Alzheimer\u2019s disease: Focus on synapse and mitochondria. Ageing Res. Rev. 73, 101529 (2022).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR283","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances. Mol. Neurodegener. 15, 30 (2020).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR284","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1474-4422(10)70277-5","volume":"10","author":"D Kapogiannis","year":"2011","unstructured":"Kapogiannis, D. & Mattson, M. P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer\u2019s disease. Lancet Neurol. 10, 187\u2013198 (2011).","journal-title":"Lancet Neurol."},{"key":"1911_CR285","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-12-23","volume":"12","author":"JA Godoy","year":"2014","unstructured":"Godoy, J. A. et al. Signaling pathway cross talk in Alzheimer\u2019s disease. Cell Commun. Signal 12, 23 (2014).","journal-title":"Cell Commun. Signal"},{"key":"1911_CR286","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/alzrt74","volume":"3","author":"A Eckert","year":"2011","unstructured":"Eckert, A., Schmitt, K. & G\u00f6tz, J. Mitochondrial dysfunction - the beginning of the end in Alzheimer\u2019s disease? Separate and synergistic modes of tau and amyloid-\u03b2 toxicity. Alzheimers Res. Ther. 3, 15 (2011).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR287","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1126\/science.1091230","volume":"304","author":"JW Lustbader","year":"2004","unstructured":"Lustbader, J. W. et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer\u2019s disease. Science 304, 448\u2013452 (2004).","journal-title":"Science"},{"key":"1911_CR288","doi-asserted-by":"publisher","first-page":"130580","DOI":"10.1016\/j.ijbiomac.2024.130580","volume":"264","author":"Z Ye","year":"2024","unstructured":"Ye, Z. et al. A\u03b2-binding with alcohol dehydrogenase drives Alzheimer\u2019s disease pathogenesis: A review. Int. J. Biol. Macromol. 264, 130580 (2024).","journal-title":"Int. J. Biol. Macromol."},{"key":"1911_CR289","doi-asserted-by":"crossref","unstructured":"Misrani, A., Tabassum, S. & Yang, L. Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease. Front. Aging Neurosci. 13, 57 (2021).","DOI":"10.3389\/fnagi.2021.617588"},{"key":"1911_CR290","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/antiox12020353","volume":"12","author":"B De Nicolo","year":"2023","unstructured":"De Nicolo, B., Cataldi-Stagetti, E., Diquigiovanni, C. & Bonora, E. Calcium and Reactive Oxygen Species Signaling Interplays in Cardiac Physiology and Pathologies. Antioxidants 12, 353 (2023).","journal-title":"Antioxidants"},{"key":"1911_CR291","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.tins.2008.06.005","volume":"31","author":"I Bezprozvanny","year":"2008","unstructured":"Bezprozvanny, I. & Mattson, M. P. Neuronal calcium mishandling and the pathogenesis of Alzheimer\u2019s disease. Trends Neurosci. 31, 454\u2013463 (2008).","journal-title":"Trends Neurosci."},{"key":"1911_CR292","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.neuroscience.2008.06.036","volume":"155","author":"R Resende","year":"2008","unstructured":"Resende, R., Ferreiro, E., Pereira, C. & Resende de Oliveira, C. Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 155, 725\u2013737 (2008).","journal-title":"Neuroscience"},{"key":"1911_CR293","doi-asserted-by":"publisher","first-page":"187","DOI":"10.15698\/cst2020.07.226","volume":"4","author":"M Calvo-Rodriguez","year":"2020","unstructured":"Calvo-Rodriguez, M. & Bacskai, B. J. High mitochondrial calcium levels precede neuronal death in vivo in Alzheimer\u2019s disease. Cell Stress 4, 187\u2013190 (2020).","journal-title":"Cell Stress"},{"key":"1911_CR294","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16074-2","volume":"11","author":"M Calvo-Rodriguez","year":"2020","unstructured":"Calvo-Rodriguez, M. et al. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer\u2019s disease. Nat. Commun. 11, 2146 (2020).","journal-title":"Nat. Commun."},{"key":"1911_CR295","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3390\/ph3061936","volume":"3","author":"H Du","year":"2010","unstructured":"Du, H. & ShiDu Yan, S. Unlocking the Door to Neuronal Woes in Alzheimer\u2019s Disease: A\u03b2 and Mitochondrial Permeability Transition Pore. Pharmaceuticals 3, 1936\u20131948 (2010).","journal-title":"Pharmaceuticals"},{"key":"1911_CR296","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tins.2020.10.004","volume":"44","author":"M Calvo-Rodriguez","year":"2021","unstructured":"Calvo-Rodriguez, M. & Bacskai, B. J. Mitochondria and Calcium in Alzheimer\u2019s Disease: From Cell Signaling to Neuronal Cell Death. Trends Neurosci. 44, 136\u2013151 (2021).","journal-title":"Trends Neurosci."},{"key":"1911_CR297","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrn3380","volume":"14","author":"S Millecamps","year":"2013","unstructured":"Millecamps, S. & Julien, J. P. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 14, 161\u2013176 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"1911_CR298","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41392-023-01547-9","volume":"8","author":"W Chen","year":"2023","unstructured":"Chen, W., Zhao, H. & Li, Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct. Target Ther. 8, 333 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR299","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1126\/science.1171091","volume":"324","author":"DH Cho","year":"2009","unstructured":"Cho, D. H. et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324, 102\u2013105 (2009).","journal-title":"Science"},{"issue":"Suppl 2","key":"1911_CR300","doi-asserted-by":"publisher","first-page":"S513","DOI":"10.3233\/JAD-2010-100552","volume":"20","author":"B Bossy","year":"2010","unstructured":"Bossy, B. et al. S-Nitrosylation of DRP1 does not affect enzymatic activity and is not specific to Alzheimer\u2019s disease. J. Alzheimers Dis. 20 (Suppl 2), S513\u2013526 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR301","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.mcn.2019.06.009","volume":"98","author":"PJ Flannery","year":"2019","unstructured":"Flannery, P. J. & Trushina, E. Mitochondrial dynamics and transport in Alzheimer\u2019s disease. Mol. Cell Neurosci. 98, 109\u2013120 (2019).","journal-title":"Mol. Cell Neurosci."},{"key":"1911_CR302","doi-asserted-by":"publisher","first-page":"101191","DOI":"10.1016\/j.arr.2020.101191","volume":"64","author":"JA Pradeepkiran","year":"2020","unstructured":"Pradeepkiran, J. A. & Reddy, P. H. Defective mitophagy in Alzheimer\u2019s disease. Ageing Res. Rev. 64, 101191 (2020).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR303","doi-asserted-by":"publisher","first-page":"101208","DOI":"10.1016\/j.arr.2020.101208","volume":"65","author":"A John","year":"2021","unstructured":"John, A. & Reddy, P. H. Synaptic basis of Alzheimer\u2019s disease: Focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res. Rev. 65, 101208 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR304","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105240","volume":"163","author":"X Li","year":"2021","unstructured":"Li, X. et al. Molecular mechanisms of mitophagy and its roles in neurodegenerative diseases. Pharm. Res. 163, 105240 (2021).","journal-title":"Pharm. Res."},{"key":"1911_CR305","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40035-022-00305-1","volume":"11","author":"K Zeng","year":"2022","unstructured":"Zeng, K. et al. Defective mitophagy and the etiopathogenesis of Alzheimer\u2019s disease. Transl. Neurodegener. 11, 32 (2022).","journal-title":"Transl. Neurodegener."},{"key":"1911_CR306","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41380-022-01631-6","volume":"28","author":"A Mary","year":"2023","unstructured":"Mary, A., Eysert, F., Checler, F. & Chami, M. Mitophagy in Alzheimer\u2019s disease: Molecular defects and therapeutic approaches. Mol. Psychiatry 28, 202\u2013216 (2023).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR307","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1002\/alz.13065","volume":"19","author":"EK Webber","year":"2023","unstructured":"Webber, E. K., Fivaz, M., Stutzmann, G. E. & Griffioen, G. Cytosolic calcium: Judge, jury and executioner of neurodegeneration in Alzheimer\u2019s disease and beyond. Alzheimers Dement. 19, 3701\u20133717 (2023).","journal-title":"Alzheimers Dement"},{"key":"1911_CR308","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.3390\/cells9122655","volume":"9","author":"J McDaid","year":"2020","unstructured":"McDaid, J., Mustaly-Kalimi, S. & Stutzmann, G. E. Ca(2+) Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer\u2019s Disease. Cells 9, 2655 (2020).","journal-title":"Cells"},{"key":"1911_CR309","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fonc.2017.00180","volume":"7","author":"G Pedriali","year":"2017","unstructured":"Pedriali, G. et al. Regulation of Endoplasmic Reticulum-Mitochondria Ca(2+) Transfer and Its Importance for Anti-Cancer Therapies. Front. Oncol. 7, 180 (2017).","journal-title":"Front. Oncol."},{"key":"1911_CR310","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fphar.2012.00061","volume":"3","author":"EM Kawamoto","year":"2012","unstructured":"Kawamoto, E. M., Vivar, C. & Camandola, S. Physiology and pathology of calcium signaling in the brain. Front. Pharm. 3, 61 (2012).","journal-title":"Front. Pharm."},{"key":"1911_CR311","doi-asserted-by":"publisher","first-page":"101678","DOI":"10.1016\/j.redox.2020.101678","volume":"36","author":"CT Madreiter-Sokolowski","year":"2020","unstructured":"Madreiter-Sokolowski, C. T., Thomas, C. & Ristow, M. Interrelation between ROS and Ca(2+) in aging and age-related diseases. Redox Biol. 36, 101678 (2020).","journal-title":"Redox Biol."},{"key":"1911_CR312","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.3390\/ijms24109067","volume":"24","author":"D Baracaldo-Santamar\u00eda","year":"2023","unstructured":"Baracaldo-Santamar\u00eda, D. et al. Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer\u2019s Disease. Int. J. Mol. Sci. 24, 9067 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1911_CR313","doi-asserted-by":"publisher","first-page":"14257","DOI":"10.3390\/ijms241814257","volume":"24","author":"S Mochida","year":"2023","unstructured":"Mochida, S. Calcium Channels and Calcium-Binding Proteins. Int J. Mol. Sci. 24, 14257 (2023).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR314","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1474-9726.2007.00275.x","volume":"6","author":"MP Mattson","year":"2007","unstructured":"Mattson, M. P. Calcium and neurodegeneration. Aging Cell 6, 337\u2013350 (2007).","journal-title":"Aging Cell"},{"key":"1911_CR315","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.molmed.2009.01.001","volume":"15","author":"I Bezprozvanny","year":"2009","unstructured":"Bezprozvanny, I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med. 15, 89\u2013100 (2009).","journal-title":"Trends Mol. Med."},{"key":"1911_CR316","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.tcb.2018.01.002","volume":"28","author":"C Giorgi","year":"2018","unstructured":"Giorgi, C. et al. Calcium Dynamics as a Machine for Decoding Signals. Trends Cell Biol. 28, 258\u2013273 (2018).","journal-title":"Trends Cell Biol."},{"key":"1911_CR317","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cardiores.2007.03.015","volume":"75","author":"S Smajilovic","year":"2007","unstructured":"Smajilovic, S. & Tfelt-Hansen, J. Calcium acts as a first messenger through the calcium-sensing receptor in the cardiovascular system. Cardiovasc. Res. 75, 457\u2013467 (2007).","journal-title":"Cardiovasc. Res"},{"key":"1911_CR318","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/joim.12562","volume":"280","author":"L Ozcan","year":"2016","unstructured":"Ozcan, L. & Tabas, I. Calcium signalling and ER stress in insulin resistance and atherosclerosis. J. Intern. Med. 280, 457\u2013464 (2016).","journal-title":"J. Intern. Med."},{"key":"1911_CR319","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.csbj.2022.11.049","volume":"21","author":"CA Crossley","year":"2023","unstructured":"Crossley, C. A., Rajani, V. & Yuan, Q. Modulation of L-type calcium channels in Alzheimer\u2019s disease: A potential therapeutic target. Comput Struct. Biotechnol. J. 21, 11\u201320 (2023).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"1911_CR320","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.nbd.2010.08.020","volume":"41","author":"TS Anekonda","year":"2011","unstructured":"Anekonda, T. S. et al. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer\u2019s disease. Neurobiol. Dis. 41, 62\u201370 (2011).","journal-title":"Neurobiol. Dis."},{"key":"1911_CR321","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"S Tu","year":"2014","unstructured":"Tu, S., Okamoto, S., Lipton, S. A. & Xu, H. Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease. Mol. Neurodegener. 9, 48 (2014).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR322","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1038\/s41380-022-01589-5","volume":"27","author":"S Li","year":"2022","unstructured":"Li, S. & Stern, A. M. Bioactive human Alzheimer brain soluble A\u03b2: pathophysiology and therapeutic opportunities. Mol. Psychiatry 27, 3182\u20133191 (2022).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR323","doi-asserted-by":"publisher","first-page":"101417","DOI":"10.1016\/j.arr.2021.101417","volume":"70","author":"MS Uddin","year":"2021","unstructured":"Uddin, M. S., Yu, W. S. & Lim, L. W. Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer\u2019s disease. Ageing Res. Rev. 70, 101417 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR324","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cophys.2020.08.010","volume":"17","author":"EJ Carvalho","year":"2020","unstructured":"Carvalho, E. J., Stathopulos, P. B. & Madesh, M. Regulation of Ca(2+) exchanges and signaling in mitochondria. Curr. Opin. Physiol. 17, 197\u2013206 (2020).","journal-title":"Curr. Opin. Physiol."},{"key":"1911_CR325","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40035-017-0092-6","volume":"6","author":"Y Liu","year":"2017","unstructured":"Liu, Y. & Zhu, X. Endoplasmic reticulum-mitochondria tethering in neurodegenerative diseases. Transl. Neurodegener. 6, 21 (2017).","journal-title":"Transl. Neurodegener."},{"key":"1911_CR326","doi-asserted-by":"publisher","first-page":"112890","DOI":"10.1016\/j.biopha.2022.112890","volume":"149","author":"J Liu","year":"2022","unstructured":"Liu, J. & Yang, J. Mitochondria-associated membranes: A hub for neurodegenerative diseases. Biomed. Pharmacother. 149, 112890 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1911_CR327","doi-asserted-by":"publisher","first-page":"7916","DOI":"10.1073\/pnas.1300677110","volume":"110","author":"L Hedskog","year":"2013","unstructured":"Hedskog, L. et al. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer\u2019s disease and related models. Proc. Natl Acad. Sci. USA 110, 7916\u20137921 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1911_CR328","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1038\/emboj.2012.202","volume":"31","author":"E Area-Gomez","year":"2012","unstructured":"Area-Gomez, E. et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 31, 4106\u20134123 (2012).","journal-title":"EMBO J."},{"key":"1911_CR329","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1042\/CS20200844","volume":"135","author":"W Yu","year":"2021","unstructured":"Yu, W., Jin, H. & Huang, Y. Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer\u2019s disease. Clin. Sci. 135, 109\u2013126 (2021).","journal-title":"Clin. Sci."},{"key":"1911_CR330","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2211999119","volume":"119","author":"S Mustaly-Kalimi","year":"2022","unstructured":"Mustaly-Kalimi, S. et al. Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 119, e2211999119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1911_CR331","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41583-022-00558-9","volume":"23","author":"FG De Felice","year":"2022","unstructured":"De Felice, F. G., Gon\u00e7alves, R. A. & Ferreira, S. T. Impaired insulin signalling and allostatic load in Alzheimer disease. Nat. Rev. Neurosci. 23, 215\u2013230 (2022).","journal-title":"Nat. Rev. Neurosci."},{"key":"1911_CR332","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","volume":"28","author":"J Nowell","year":"2023","unstructured":"Nowell, J., Blunt, E. & Edison, P. Incretin and insulin signaling as novel therapeutic targets for Alzheimer\u2019s and Parkinson\u2019s disease. Mol. Psychiatry 28, 217\u2013229 (2023).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR333","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.arr.2011.01.001","volume":"10","author":"SC Correia","year":"2011","unstructured":"Correia, S. C. et al. Insulin-resistant brain state: the culprit in sporadic Alzheimer\u2019s disease? Ageing Res. Rev. 10, 264\u2013273 (2011).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR334","doi-asserted-by":"publisher","first-page":"101979","DOI":"10.1016\/j.arr.2023.101979","volume":"89","author":"J Nowell","year":"2023","unstructured":"Nowell, J., Blunt, E., Gupta, D. & Edison, P. Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease. Ageing Res. Rev. 89, 101979 (2023).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR335","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","volume":"19","author":"D Kellar","year":"2020","unstructured":"Kellar, D. & Craft, S. Brain insulin resistance in Alzheimer\u2019s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 19, 758\u2013766 (2020).","journal-title":"Lancet Neurol."},{"key":"1911_CR336","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-2005-7107","volume":"7","author":"E Steen","year":"2005","unstructured":"Steen, E. et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease\u2013is this type 3 diabetes? J. Alzheimers Dis. 7, 63\u201380 (2005).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR337","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fnins.2019.00629","volume":"13","author":"S Gabbouj","year":"2019","unstructured":"Gabbouj, S. et al. Altered Insulin Signaling in Alzheimer\u2019s Disease Brain - Special Emphasis on PI3K-Akt Pathway. Front. Neurosci. 13, 629 (2019).","journal-title":"Front. Neurosci."},{"key":"1911_CR338","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","volume":"104","author":"C Hooper","year":"2008","unstructured":"Hooper, C., Killick, R. & Lovestone, S. The GSK3 hypothesis of Alzheimer\u2019s disease. J. Neurochem. 104, 1433\u20131439 (2008).","journal-title":"J. Neurochem."},{"key":"1911_CR339","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.tem.2011.12.004","volume":"23","author":"B Kim","year":"2012","unstructured":"Kim, B. & Feldman, E. L. Insulin resistance in the nervous system. Trends Endocrinol. Metab. 23, 133\u2013141 (2012).","journal-title":"Trends Endocrinol. Metab."},{"key":"1911_CR340","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13024-021-00428-5","volume":"16","author":"H Querfurth","year":"2021","unstructured":"Querfurth, H. & Lee, H. K. Mammalian\/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Mol. Neurodegener. 16, 44 (2021).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR341","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1172\/JCI57256","volume":"122","author":"TR Bomfim","year":"2012","unstructured":"Bomfim, T. R. et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease- associated A\u03b2 oligomers. J. Clin. Invest. 122, 1339\u20131353 (2012).","journal-title":"J. Clin. Invest."},{"key":"1911_CR342","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrd3366","volume":"10","author":"AH Nagahara","year":"2011","unstructured":"Nagahara, A. H. & Tuszynski, M. H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. 10, 209\u2013219 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1911_CR343","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41386-023-01717-x","volume":"49","author":"J Kim","year":"2024","unstructured":"Kim, J., He, M. J., Widmann, A. K. & Lee, F. S. The role of neurotrophic factors in novel, rapid psychiatric treatments. Neuropsychopharmacology 49, 227\u2013245 (2024).","journal-title":"Neuropsychopharmacology"},{"key":"1911_CR344","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1038\/s41380-020-0797-2","volume":"26","author":"R Pentz","year":"2021","unstructured":"Pentz, R. et al. The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Mol. Psychiatry 26, 6023\u20136037 (2021).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR345","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/acel.12473","volume":"15","author":"V Triaca","year":"2016","unstructured":"Triaca, V. et al. NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer\u2019s disease. Aging Cell 15, 661\u2013672 (2016).","journal-title":"Aging Cell"},{"key":"1911_CR346","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1093\/brain\/awab460","volume":"145","author":"K Xhima","year":"2022","unstructured":"Xhima, K. et al. Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies. Brain 145, 2806\u20132822 (2022).","journal-title":"Brain"},{"key":"1911_CR347","doi-asserted-by":"publisher","first-page":"165858","DOI":"10.1016\/j.bbadis.2020.165858","volume":"1866","author":"XW Ding","year":"2020","unstructured":"Ding, X. W. et al. Nerve growth factor in metabolic complications and Alzheimer\u2019s disease: Physiology and therapeutic potential. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165858 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1911_CR348","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/0896-6273(91)90273-3","volume":"7","author":"HS Phillips","year":"1991","unstructured":"Phillips, H. S. et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer\u2019s disease. Neuron 7, 695\u2013702 (1991).","journal-title":"Neuron"},{"key":"1911_CR349","doi-asserted-by":"publisher","first-page":"9094","DOI":"10.1073\/pnas.1901348116","volume":"116","author":"J Xiang","year":"2019","unstructured":"Xiang, J. et al. Delta-secretase-cleaved Tau antagonizes TrkB neurotrophic signalings, mediating Alzheimer\u2019s disease pathologies. Proc. Natl Acad. Sci. USA 116, 9094\u20139102 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1911_CR350","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2100986118","volume":"118","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. Neurotrophic signaling deficiency exacerbates environmental risks for Alzheimer\u2019s disease pathogenesis. Proc. Natl Acad. Sci. USA 118, e2100986118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1911_CR351","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.celrep.2019.06.054","volume":"28","author":"ZH Wang","year":"2019","unstructured":"Wang, Z. H. et al. Deficiency in BDNF\/TrkB Neurotrophic Activity Stimulates \u03b4-Secretase by Upregulating C\/EBP\u03b2 in Alzheimer\u2019s Disease. Cell Rep. 28, 655\u2013669.e5 (2019).","journal-title":"Cell Rep."},{"key":"1911_CR352","doi-asserted-by":"publisher","first-page":"13139","DOI":"10.1073\/pnas.0806133105","volume":"105","author":"C Matrone","year":"2008","unstructured":"Matrone, C. et al. NGF and BDNF signaling control amyloidogenic route and Abeta production in hippocampal neurons. Proc. Natl Acad. Sci. USA 105, 13139\u201313144 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1911_CR353","doi-asserted-by":"publisher","first-page":"6799","DOI":"10.1523\/JNEUROSCI.5463-03.2004","volume":"24","author":"L Tong","year":"2004","unstructured":"Tong, L., Balazs, R., Thornton, P. L. & Cotman, C. W. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci. 24, 6799\u20136809 (2004).","journal-title":"J. Neurosci."},{"key":"1911_CR354","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbi.2023.07.011","volume":"113","author":"W Wang","year":"2023","unstructured":"Wang, W. et al. Microglial repopulation reverses cognitive and synaptic deficits in an Alzheimer\u2019s disease model by restoring BDNF signaling. Brain Behav. Immun. 113, 275\u2013288 (2023).","journal-title":"Brain Behav. Immun."},{"key":"1911_CR355","doi-asserted-by":"publisher","first-page":"16288","DOI":"10.3390\/ijms242216288","volume":"24","author":"AE Alkhalifa","year":"2023","unstructured":"Alkhalifa, A. E. et al. Blood-Brain Barrier Breakdown in Alzheimer\u2019s Disease: Mechanisms and Targeted Strategies. Int J. Mol. Sci. 24, 16288 (2023).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR356","doi-asserted-by":"publisher","first-page":"108119","DOI":"10.1016\/j.pharmthera.2022.108119","volume":"234","author":"G Nehra","year":"2022","unstructured":"Nehra, G., Bauer, B. & Hartz, A. M. S. Blood-brain barrier leakage in Alzheimer\u2019s disease: From discovery to clinical relevance. Pharm. Ther. 234, 108119 (2022).","journal-title":"Pharm. Ther."},{"key":"1911_CR357","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114517","volume":"189","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Opportunities and challenges in delivering biologics for Alzheimer\u2019s disease by low-intensity ultrasound. Adv. Drug Deliv. Rev. 189, 114517 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1911_CR358","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","volume":"12","author":"BV Zlokovic","year":"2011","unstructured":"Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat. Rev. Neurosci. 12, 723\u2013738 (2011).","journal-title":"Nat. Rev. Neurosci."},{"key":"1911_CR359","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3389\/fnins.2019.01452","volume":"13","author":"AH Bell","year":"2019","unstructured":"Bell, A. H., Miller, S. L., Castillo-Melendez, M. & Malhotra, A. The Neurovascular Unit: Effects of Brain Insults During the Perinatal Period. Front. Neurosci. 13, 1452 (2019).","journal-title":"Front. Neurosci."},{"key":"1911_CR360","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1084\/jem.20171406","volume":"214","author":"A Montagne","year":"2017","unstructured":"Montagne, A., Zhao, Z. & Zlokovic, B. V. Alzheimer\u2019s disease: A matter of blood-brain barrier dysfunction? J. Exp. Med. 214, 3151\u20133169 (2017).","journal-title":"J. Exp. Med."},{"key":"1911_CR361","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.addr.2018.04.009","volume":"135","author":"Y Pan","year":"2018","unstructured":"Pan, Y. & Nicolazzo, J. A. Impact of aging, Alzheimer\u2019s disease and Parkinson\u2019s disease on the blood-brain barrier transport of therapeutics. Adv. Drug Deliv. Rev. 135, 62\u201374 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1911_CR362","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nbd.2016.07.007","volume":"107","author":"E Zenaro","year":"2017","unstructured":"Zenaro, E., Piacentino, G. & Constantin, G. The blood-brain barrier in Alzheimer\u2019s disease. Neurobiol. Dis. 107, 41\u201356 (2017).","journal-title":"Neurobiol. Dis."},{"key":"1911_CR363","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/jcbfm.2013.135","volume":"33","author":"MA Erickson","year":"2013","unstructured":"Erickson, M. A. & Banks, W. A. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer\u2019s disease. J. Cereb. Blood Flow. Metab. 33, 1500\u20131513, (2013).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"1911_CR364","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nn.3966","volume":"18","author":"EA Winkler","year":"2015","unstructured":"Winkler, E. A. et al. GLUT1 reductions exacerbate Alzheimer\u2019s disease vasculo-neuronal dysfunction and degeneration. Nat. Neurosci. 18, 521\u2013530 (2015).","journal-title":"Nat. Neurosci."},{"key":"1911_CR365","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA\u2010AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"1911_CR366","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101544","volume":"74","author":"YAR Mahaman","year":"2022","unstructured":"Mahaman, Y. A. R. et al. Biomarkers used in Alzheimer\u2019s disease diagnosis, treatment, and prevention. Ageing Res. Rev. 74, 101544 (2022).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR367","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens, P. et al. Alzheimer\u2019s disease. Lancet 397, 1577\u20131590 (2021).","journal-title":"Lancet"},{"key":"1911_CR368","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40035-022-00296-z","volume":"11","author":"TO Klyucherev","year":"2022","unstructured":"Klyucherev, T. O. et al. Advances in the development of new biomarkers for Alzheimer\u2019s disease. Transl. Neurodegener. 11, 25 (2022).","journal-title":"Transl. Neurodegener."},{"key":"1911_CR369","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1148\/rg.343135065","volume":"34","author":"BN Brown RK","year":"2014","unstructured":"Brown RK, B. N.Wong, K. K., Minoshima, S. & Frey, K. A. Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics 34, 684\u2013701 (2014).","journal-title":"Radiographics"},{"key":"1911_CR370","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.3390\/ijms22042110","volume":"22","author":"WM van Oostveen","year":"2021","unstructured":"van Oostveen, W. M. & de Lange, E. C. M. Imaging Techniques in Alzheimer\u2019s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. Int J. Mol. Sci. 22, 2110 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR371","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2021.100041","volume":"5","author":"E Andersen","year":"2021","unstructured":"Andersen, E. et al. Diagnostic biomarkers in Alzheimer\u2019s disease. Biomark. Neuropsychiatry 5, 100041 (2021).","journal-title":"Biomark. Neuropsychiatry"},{"key":"1911_CR372","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 15, 673\u2013684 (2016).","journal-title":"Lancet Neurol."},{"key":"1911_CR373","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 13, 614\u2013629 (2014).","journal-title":"Lancet Neurol."},{"key":"1911_CR374","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","volume":"26","author":"M Bucci","year":"2021","unstructured":"Bucci, M., Chiotis, K. & Nordberg, A. Alzheimer\u2019s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol. Psychiatry 26, 5888\u20135898 (2021).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR375","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","volume":"390","author":"J Jia","year":"2024","unstructured":"Jia, J. et al. Biomarker Changes during 20 Years Preceding Alzheimer\u2019s Disease. N. Engl. J. Med. 390, 712\u2013722 (2024).","journal-title":"N. Engl. J. Med"},{"key":"1911_CR376","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158708","volume":"132","author":"A Zhao","year":"2022","unstructured":"Zhao, A. et al. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease. J. Clin. Invest. 132, e158708 (2022).","journal-title":"J. Clin. Invest"},{"key":"1911_CR377","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/alz.12618","volume":"18","author":"H Zetterberg","year":"2022","unstructured":"Zetterberg, H. Biofluid\u2010based biomarkers for Alzheimer\u2019s disease\u2013related pathologies: An update and synthesis of the literature. Alzheimers Dement. 18, 1687\u20131693 (2022).","journal-title":"Alzheimers Dement."},{"key":"1911_CR378","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molmed.2018.11.006","volume":"25","author":"SF Carter","year":"2019","unstructured":"Carter, S. F. et al. Astrocyte Biomarkers in Alzheimer\u2019s Disease. Trends Mol. Med. 25, 77\u201395 (2019).","journal-title":"Trends Mol. Med."},{"key":"1911_CR379","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1176\/appi.ajp.2021.19080873","volume":"178","author":"A Kumar","year":"2021","unstructured":"Kumar, A. et al. Amyloid and Tau in Alzheimer\u2019s Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger? Am. J. Psychiatry 178, 1014\u20131025 (2021).","journal-title":"Am. J. Psychiatry"},{"key":"1911_CR380","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation, D. A. et al. Blood\u2013brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med. 25, 270\u2013276 (2019).","journal-title":"Nat. Med."},{"key":"1911_CR381","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jalz.2017.01.008","volume":"13","author":"MW Wong","year":"2017","unstructured":"Wong, M. W. et al. Dysregulation of lipids in Alzheimer\u2019s disease and their role as potential biomarkers. Alzheimers Dement. 13, 810\u2013827 (2017).","journal-title":"Alzheimers Dement."},{"key":"1911_CR382","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13195-023-01269-8","volume":"15","author":"S Paciotti","year":"2023","unstructured":"Paciotti, S. et al. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer\u2019s disease continuum. Alzheimers Res. Ther. 15, 124 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR383","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/brain\/awad361","volume":"147","author":"K Yuyama","year":"2023","unstructured":"Yuyama, K. et al. Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer\u2019s disease pathogenesis. Brain 147, 627\u2013636 (2023).","journal-title":"Brain"},{"key":"1911_CR384","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1002\/alz.13066","volume":"19","author":"M Chatterjee","year":"2023","unstructured":"Chatterjee, M. et al. C1q is increased in cerebrospinal fluid\u2010derived extracellular vesicles in Alzheimer\u2019s disease: A multi\u2010cohort proteomics and immuno\u2010assay validation study. Alzheimers Dement. 19, 4828\u20134840 (2023).","journal-title":"Alzheimers Dement."},{"key":"1911_CR385","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1002\/alz.13455","volume":"19","author":"K Blennow","year":"2023","unstructured":"Blennow, K. et al. The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 19, 5805\u20135816 (2023).","journal-title":"Alzheimers Dement."},{"key":"1911_CR386","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s10571-023-01330-y","volume":"43","author":"S Rani","year":"2023","unstructured":"Rani, S. et al. Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer\u2019s Disease. Cell Mol. Neurobiol. 43, 2491\u20132523 (2023).","journal-title":"Cell Mol. Neurobiol."},{"key":"1911_CR387","doi-asserted-by":"publisher","first-page":"114278","DOI":"10.1016\/j.bios.2022.114278","volume":"210","author":"S Hu","year":"2022","unstructured":"Hu, S., Yang, C. & Luo, H. Current trends in blood biomarker detection and imaging for Alzheimer\u2019s disease. Biosens. Bioelectron. 210, 114278 (2022).","journal-title":"Biosens. Bioelectron."},{"key":"1911_CR388","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"1911_CR389","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow, K. & Zetterberg, H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J. Intern. Med. 284, 643\u2013663 (2018).","journal-title":"J. Intern. Med."},{"key":"1911_CR390","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/alz.13676","volume":"20","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer\u2019s disease across ethnic groups. Alzheimers Dement. 20, 2000\u20132015 (2024).","journal-title":"Alzheimers Dement"},{"key":"1911_CR391","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.4103\/1673-5374.335791","volume":"17","author":"M Valenza","year":"2022","unstructured":"Valenza, M. & Scuderi, C. How useful are biomarkers for the diagnosis of Alzheimer\u2019s disease and especially for its therapy? Neural Regen. Res. 17, 2205\u20132207 (2022).","journal-title":"Neural Regen. Res."},{"key":"1911_CR392","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-022-01875-3","volume":"28","author":"SE Schindler","year":"2022","unstructured":"Schindler, S. E. & Karikari, T. K. Comorbidities confound Alzheimer\u2019s blood tests. Nat. Med. 28, 1349\u20131351 (2022).","journal-title":"Nat. Med."},{"key":"1911_CR393","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/alz.12647","volume":"19","author":"SE O\u2019Bryant","year":"2023","unstructured":"O\u2019Bryant, S. E., Petersen, M., Hall, J. & Johnson, L. A. Medical comorbidities and ethnicity impact plasma Alzheimer\u2019s disease biomarkers: Important considerations for clinical trials and practice. Alzheimers Dement. 19, 36\u201343 (2023).","journal-title":"Alzheimers Dement."},{"key":"1911_CR394","doi-asserted-by":"publisher","first-page":"e2303","DOI":"10.1212\/WNL.0000000000201202","volume":"99","author":"KAQ Cousins","year":"2022","unstructured":"Cousins, K. A. Q. et al. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant \u03b1-Synuclein Pathology. Neurology 99, e2303\u2013e2312 (2022).","journal-title":"Neurology"},{"key":"1911_CR395","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398\u20131405 (2022).","journal-title":"Nat. Med."},{"key":"1911_CR396","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/13543784.2016.1216972","volume":"25","author":"D Galimberti","year":"2016","unstructured":"Galimberti, D. & Scarpini, E. Old and new acetylcholinesterase inhibitors for Alzheimer\u2019s disease. Expert Opin. Investig. Drugs 25, 1181\u20131187 (2016).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1911_CR397","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters, C. L. et al. Alzheimer\u2019s disease. Nat. Rev. Dis. Prim. 1, 15056 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1911_CR398","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2174\/1389557520666200103100521","volume":"20","author":"H Ak\u0131nc\u0131o\u011flu","year":"2020","unstructured":"Ak\u0131nc\u0131o\u011flu, H. & G\u00fcl\u00e7in, \u0130. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer\u2019s Disease. Mini Rev. Med. Chem. 20, 703\u2013715 (2020).","journal-title":"Mini Rev. Med. Chem."},{"key":"1911_CR399","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s00204-019-02538-y","volume":"93","author":"M Simunkova","year":"2019","unstructured":"Simunkova, M. et al. Management of oxidative stress and other pathologies in Alzheimer\u2019s disease. Arch. Toxicol. 93, 2491\u20132513 (2019).","journal-title":"Arch. Toxicol."},{"key":"1911_CR400","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1517\/14740338.3.5.425","volume":"3","author":"S Thompson","year":"2004","unstructured":"Thompson, S., Lanct\u00f4t, K. L. & Herrmann, N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer\u2019s disease. Expert Opin. Drug Saf. 3, 425\u2013440 (2004).","journal-title":"Expert Opin. Drug Saf."},{"key":"1911_CR401","first-page":"2296","volume":"14","author":"D Nunes","year":"2022","unstructured":"Nunes, D., Loureiro, J. A. & Pereira, M. C. Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer\u2019s. Drugs Pharm. 14, 2296 (2022).","journal-title":"Drugs Pharm."},{"key":"1911_CR402","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.3390\/ijms21093272","volume":"21","author":"MT Kabir","year":"2020","unstructured":"Kabir, M. T. et al. Combination Drug Therapy for the Management of Alzheimer\u2019s Disease. Int. J. Mol. Sci. 21, 3272 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1911_CR403","doi-asserted-by":"publisher","first-page":"l6217","DOI":"10.1136\/bmj.l6217","volume":"367","author":"E Joe","year":"2019","unstructured":"Joe, E. & Ringman, J. M. Cognitive symptoms of Alzheimer\u2019s disease: clinical management and prevention. BMJ 367, l6217 (2019).","journal-title":"BMJ"},{"key":"1911_CR404","first-page":"1642","volume":"327","author":"HD Larkin","year":"2022","unstructured":"Larkin, H. D. First Donepezil Transdermal Patch Approved for Alzheimer Disease. JAMA 327, 1642 (2022).","journal-title":"JAMA"},{"key":"1911_CR405","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3233\/JAD-220530","volume":"90","author":"PN Tariot","year":"2022","unstructured":"Tariot, P. N., Braeckman, R. & Oh, C. Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil. J. Alzheimers Dis. 90, 161\u2013172 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR406","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/pharmaceutics15051399","volume":"15","author":"R Tal\u00e9ns-Visconti","year":"2023","unstructured":"Tal\u00e9ns-Visconti, R. et al. Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. Pharmaceutics 15, 1399 (2023).","journal-title":"Pharmaceutics"},{"key":"1911_CR407","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/pharmaceutics15030829","volume":"15","author":"D Georgieva","year":"2023","unstructured":"Georgieva, D., Nikolova, D., Vassileva, E. & Kostova, B. Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer\u2019s Disease Therapy. Pharmaceutics 15, 829 (2023).","journal-title":"Pharmaceutics"},{"key":"1911_CR408","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/brainsci11020184","volume":"11","author":"H Amat-Ur-Rasool","year":"2021","unstructured":"Amat-Ur-Rasool, H., Ahmed, M., Hasnain, S. & Carter, W. G. Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer\u2019s Disease. Brain Sci. 11, 184 (2021).","journal-title":"Brain Sci."},{"key":"1911_CR409","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cells12010131","volume":"12","author":"DC Miculas","year":"2022","unstructured":"Miculas, D. C. et al. Pharmacotherapy Evolution in Alzheimer\u2019s Disease: Current Framework and Relevant Directions. Cells 12, 131 (2022).","journal-title":"Cells"},{"key":"1911_CR410","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/pharmaceutics14061117","volume":"14","author":"T Pardo-Moreno","year":"2022","unstructured":"Pardo-Moreno, T. et al. Therapeutic Approach to Alzheimer\u2019s Disease: Current Treatments and New Perspectives. Pharmaceutics 14, 1117 (2022).","journal-title":"Pharmaceutics"},{"key":"1911_CR411","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","volume":"27","author":"LK Huang","year":"2020","unstructured":"Huang, L. K., Chao, S. P. & Hu, C. J. Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci. 27, 18 (2020).","journal-title":"J. Biomed. Sci."},{"key":"1911_CR412","first-page":"109","volume":"4","author":"J Cummings","year":"2017","unstructured":"Cummings, J. & Fox, N. Defining Disease Modifying Therapy for Alzheimer\u2019s Disease. J. Prev. Alzheimers Dis. 4, 109\u2013115 (2017).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1911_CR413","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11948-022-00422-0","volume":"29","author":"NSL Yeo-Teh","year":"2023","unstructured":"Yeo-Teh, N. S. L. & Tang, B. L. A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer\u2019s Disease. Sci. Eng. Ethics 29, 2 (2023).","journal-title":"Sci. Eng. Ethics"},{"key":"1911_CR414","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","volume":"29","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression. Cell Res. 29, 787\u2013803 (2019).","journal-title":"Cell Res."},{"key":"1911_CR415","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13024-023-00700-w","volume":"19","author":"ME Bosch","year":"2024","unstructured":"Bosch, M. E. et al. Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner. Mol. Neurodegener. 19, 18 (2024).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR416","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-021-00557-x","volume":"17","author":"KY Liu","year":"2021","unstructured":"Liu, K. Y. & Howard, R. Can we learn lessons from the FDA\u2019s approval of aducanumab? Nat. Rev. Neurol. 17, 715\u2013722 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1911_CR417","doi-asserted-by":"publisher","first-page":"e069780","DOI":"10.1136\/bmj-2021-069780","volume":"376","author":"MP Lythgoe","year":"2022","unstructured":"Lythgoe, M. P., Jenei, K. & Prasad, V. Regulatory decisions diverge over aducanumab for Alzheimer\u2019s disease. BMJ 376, e069780 (2022).","journal-title":"BMJ"},{"key":"1911_CR418","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"1911_CR419","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran, E. & De Strooper, B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat. Rev. Drug Discov. 21, 306\u2013318 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1911_CR420","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","volume":"186","author":"M Jucker","year":"2023","unstructured":"Jucker, M. & Walker, L. C. Alzheimer\u2019s disease: From immunotherapy to immunoprevention. Cell 186, 4260\u20134270 (2023).","journal-title":"Cell"},{"key":"1911_CR421","doi-asserted-by":"publisher","first-page":"P1601","DOI":"10.1016\/j.jalz.2019.09.068","volume":"15","author":"L Lannfelt","year":"2019","unstructured":"Lannfelt, L. et al. BAN2401 shows stronger binding to soluble aggregated amyloid-beta species than aducanumab. Alzheimers Dement. 15, P1601\u2013P1602 (2019).","journal-title":"Alzheimers Dement."},{"key":"1911_CR422","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1126\/science.adj9255","volume":"382","author":"TE Golde","year":"2023","unstructured":"Golde, T. E. & Levey, A. I. Immunotherapies for Alzheimer\u2019s disease. Science 382, 1242\u20131244 (2023).","journal-title":"Science"},{"key":"1911_CR423","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","volume":"186","author":"AL Boxer","year":"2023","unstructured":"Boxer, A. L. & Sperling, R. Accelerating Alzheimer\u2019s therapeutic development: The past and future of clinical trials. Cell 186, 4757\u20134772 (2023).","journal-title":"Cell"},{"key":"1911_CR424","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.adk0830","volume":"381","author":"J Couzin-Frankel","year":"2023","unstructured":"Couzin-Frankel, J. Side effects loom over Alzheimer\u2019s drugs. Science 381, 466\u2013467 (2023).","journal-title":"Science"},{"key":"1911_CR425","doi-asserted-by":"publisher","first-page":"1034243","DOI":"10.3389\/fneur.2022.1034243","volume":"13","author":"Y Cao","year":"2022","unstructured":"Cao, Y., Yu, F., Lyu, Y. & Lu, X. Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer\u2019s disease in China. Front. Neurol. 13, 1034243 (2022).","journal-title":"Front. Neurol."},{"key":"1911_CR426","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1001\/jamaneurol.2023.3967","volume":"80","author":"C Ballard","year":"2023","unstructured":"Ballard, C. Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimer Disease. JAMA Neurol. 80, 1272\u20131273 (2023).","journal-title":"JAMA Neurol."},{"key":"1911_CR427","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jagp.2019.11.004","volume":"28","author":"OP Almeida","year":"2020","unstructured":"Almeida, O. P. & Ford, A. H. Are We Getting Better at Managing Agitation in Dementia? Am. J. Geriatr. Psychiatry 28, 401\u2013403 (2020).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"1911_CR428","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-020-00662-x","volume":"12","author":"J Bauzon","year":"2020","unstructured":"Bauzon, J., Lee, G. & Cummings, J. Repurposed agents in the Alzheimer\u2019s disease drug development pipeline. Alzheimers Res. Ther. 12, 98 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR429","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1257700","volume":"14","author":"ME Grabowska","year":"2023","unstructured":"Grabowska, M. E. et al. Drug repurposing for Alzheimer\u2019s disease from 2012-2022-a 10-year literature review. Front. Pharm. 14, 1257700 (2023).","journal-title":"Front. Pharm."},{"key":"1911_CR430","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","volume":"16","author":"C Ballard","year":"2020","unstructured":"Ballard, C. et al. Drug repositioning and repurposing for Alzheimer disease. Nat. Rev. Neurol. 16, 661\u2013673 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1911_CR431","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43929-1","volume":"14","author":"C Zang","year":"2023","unstructured":"Zang, C. et al. High-throughput target trial emulation for Alzheimer\u2019s disease drug repurposing with real-world data. Nat. Commun. 14, 8180 (2023).","journal-title":"Nat. Commun."},{"key":"1911_CR432","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21330-0","volume":"12","author":"S Rodriguez","year":"2021","unstructured":"Rodriguez, S. et al. Machine learning identifies candidates for drug repurposing in Alzheimer\u2019s disease. Nat. Commun. 12, 1033 (2021).","journal-title":"Nat. Commun."},{"key":"1911_CR433","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13195-021-00826-3","volume":"13","author":"S Tsuji","year":"2021","unstructured":"Tsuji, S. et al. Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer\u2019s disease. Alzheimers Res. Ther. 13, 92 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR434","first-page":"e12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement. 9, e12385 (2023).","journal-title":"Alzheimers Dement."},{"key":"1911_CR435","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13195-021-00927-z","volume":"13","author":"P van Bokhoven","year":"2021","unstructured":"van Bokhoven, P. et al. The Alzheimer\u2019s disease drug development landscape. Alzheimers Res. Ther. 13, 186 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR436","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JAD-190507","volume":"71","author":"DR Elmaleh","year":"2019","unstructured":"Elmaleh, D. R. et al. Developing Effective Alzheimer\u2019s Disease Therapies: Clinical Experience and Future Directions. J. Alzheimers Dis. 71, 715\u2013732 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR437","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s41401-020-00565-5","volume":"42","author":"F Zhang","year":"2021","unstructured":"Zhang, F. et al. New therapeutics beyond amyloid-\u03b2 and tau for the treatment of Alzheimer\u2019s disease. Acta Pharm. Sin. 42, 1382\u20131389 (2021).","journal-title":"Acta Pharm. Sin."},{"key":"1911_CR438","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 369, 341\u2013350 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR439","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/nm.3365","volume":"19","author":"K Blennow","year":"2013","unstructured":"Blennow, K., Zetterberg, H., Haass, C. & Finucane, T. Semagacestat\u2019s fall: where next for AD therapies? Nat. Med. 19, 1214\u20131215 (2013).","journal-title":"Nat. Med."},{"key":"1911_CR440","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cell.2020.11.049","volume":"184","author":"G Yang","year":"2021","unstructured":"Yang, G. et al. Structural basis of \u03b3-secretase inhibition and modulation by small molecule drugs. Cell 184, 521\u2013533.e14 (2021).","journal-title":"Cell"},{"key":"1911_CR441","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1056\/NEJMc1310845","volume":"369","author":"VB Gupta","year":"2013","unstructured":"Gupta, V. B., Gupta, V. K. & Martins, R. Semagacestat for treatment of Alzheimer\u2019s disease. N. Engl. J. Med. 369, 1660\u20131661, (2013).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR442","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric, V. et al. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. JAMA Neurol. 72, 1324\u20131333 (2015).","journal-title":"JAMA Neurol."},{"key":"1911_CR443","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1038\/475S9a","volume":"475","author":"L Gravitz","year":"2011","unstructured":"Gravitz, L. Drugs: a tangled web of targets. Nature 475, S9\u201311 (2011).","journal-title":"Nature"},{"key":"1911_CR444","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/1570159X18666200503023323","volume":"19","author":"M Hrabinova","year":"2021","unstructured":"Hrabinova, M. et al. Is It the Twilight of BACE1 Inhibitors? Curr. Neuropharmacol. 19, 61\u201377 (2021).","journal-title":"Curr. Neuropharmacol."},{"key":"1911_CR445","doi-asserted-by":"publisher","first-page":"e9316","DOI":"10.15252\/emmm.201809316","volume":"10","author":"U Neumann","year":"2018","unstructured":"Neumann, U. et al. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer\u2019s disease. EMBO Mol. Med. 10, e9316 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1911_CR446","doi-asserted-by":"publisher","first-page":"101496","DOI":"10.1016\/j.arr.2021.101496","volume":"72","author":"D Jeremic","year":"2021","unstructured":"Jeremic, D., Jim\u00e9nez-D\u00edaz, L. & Navarro-L\u00f3pez, J. D. Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer\u2019s disease: a systematic review. Ageing Res. Rev. 72, 101496 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR447","first-page":"453","volume":"10","author":"T Walsh","year":"2023","unstructured":"Walsh, T. et al. Outreach, Screening, and Randomization of APOE \u03b54 Carriers into an Alzheimer\u2019s Prevention Trial: A global Perspective from the API Generation Program. J. Prev. Alzheimers Dis. 10, 453\u2013463 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1911_CR448","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","volume":"28","author":"BP Imbimbo","year":"2019","unstructured":"Imbimbo, B. P. & Watling, M. Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin. Investig. Drugs 28, 967\u2013975 (2019).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1911_CR449","first-page":"50","volume":"10","author":"N Navarro-G\u00f3mez","year":"2023","unstructured":"Navarro-G\u00f3mez, N., Valdes-Gonzalez, M., Garrido-Su\u00e1rez, B. B. & Garrido, G. Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010\u20132020. J. Prev. Alzheimers Dis. 10, 50\u201368 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1911_CR450","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","volume":"12","author":"M Tolar","year":"2020","unstructured":"Tolar, M. et al. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval. Alzheimers Res. Ther. 12, 95 (2020).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR451","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","volume":"16","author":"M Tolar","year":"2020","unstructured":"Tolar, M., Abushakra, S. & Sabbagh, M. The path forward in Alzheimer\u2019s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 16, 1553\u20131560 (2020).","journal-title":"Alzheimers Dement."},{"key":"1911_CR452","doi-asserted-by":"publisher","first-page":"11791","DOI":"10.3390\/ijms222111791","volume":"22","author":"T Hoffmann","year":"2021","unstructured":"Hoffmann, T. et al. Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain A\u03b2 Pathology in Transgenic Mice. Int J. Mol. Sci. 22, 11791 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR453","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114837","volume":"244","author":"N Van Manh","year":"2022","unstructured":"Van Manh, N. et al. Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer\u2019s disease agents. Eur. J. Med. Chem. 244, 114837 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR454","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","volume":"10","author":"P Scheltens","year":"2018","unstructured":"Scheltens, P. et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer\u2019s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res. Ther. 10, 107 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR455","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13195-021-00882-9","volume":"13","author":"EGB Vijverberg","year":"2021","unstructured":"Vijverberg, E. G. B. et al. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD. Alzheimers Res. Ther. 13, 142 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR456","doi-asserted-by":"crossref","unstructured":"The, L. Alzheimer\u2019s disease: expedition into the unknown. Lancet. 388, 2713 (2016).","DOI":"10.1016\/S0140-6736(16)32457-6"},{"key":"1911_CR457","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMp1701047","volume":"376","author":"CA Sacks","year":"2017","unstructured":"Sacks, C. A., Avorn, J. & Kesselheim, A. S. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. N. Engl. J. Med. 376, 1706\u20131708 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR458","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1056\/NEJMe1313943","volume":"370","author":"E Karran","year":"2014","unstructured":"Karran, E. & Hardy, J. Antiamyloid therapy for Alzheimer\u2019s disease\u2013are we on the right road? N. Engl. J. Med. 370, 377\u2013378 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR459","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig, L. S. et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer\u2019s Disease. N. Engl. J. Med. 378, 321\u2013330 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR460","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","volume":"14","author":"RJ Bateman","year":"2022","unstructured":"Bateman, R. J. et al. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer\u2019s disease. Alzheimers Res. Ther. 14, 178 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR461","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman, R. J. et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer\u2019s Disease. N. Engl. J. Med. 389, 1862\u20131876 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR462","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMe2310903","volume":"389","author":"LS Schneider","year":"2023","unstructured":"Schneider, L. S. What the Gantenerumab Trials Teach Us about Alzheimer\u2019s Treatment. N. Engl. J. Med. 389, 1918\u20131920 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1911_CR463","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/s41380-023-02113-z","volume":"28","author":"N Basheer","year":"2023","unstructured":"Basheer, N. et al. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer\u2019s disease? From preclinical studies to the clinical trials. Mol. Psychiatry 28, 2197\u20132214 (2023).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR464","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106446","volume":"134","author":"Y Dong","year":"2023","unstructured":"Dong, Y. et al. Design, synthesis and bioevaluation of 1,2,4-thiadiazolidine-3,5-dione derivatives as potential GSK-3beta inhibitors for the treatment of Alzheimer\u2019s disease. Bioorg. Chem. 134, 106446 (2023).","journal-title":"Bioorg. Chem."},{"key":"1911_CR465","doi-asserted-by":"publisher","first-page":"S611","DOI":"10.3233\/JAD-179935","volume":"64","author":"W Gulisano","year":"2018","unstructured":"Gulisano, W. et al. Role of Amyloid-\u03b2 and Tau Proteins in Alzheimer\u2019s Disease: Confuting the Amyloid Cascade. J. Alzheimers Dis. 64, S611\u2013S631 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR466","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-170560","volume":"61","author":"GK Wilcock","year":"2018","unstructured":"Wilcock, G. K. et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer\u2019s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. J. Alzheimers Dis. 61, 435\u2013457 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR467","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier, S. et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388, 2873\u20132884 (2016).","journal-title":"Lancet"},{"key":"1911_CR468","first-page":"780","volume":"9","author":"CM Wischik","year":"2022","unstructured":"Wischik, C. M. et al. Oral Tau Aggregation Inhibitor for Alzheimer\u2019s Disease: Design, Progress and Basis for Selection of the 16 mg\/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. J. Prev. Alzheimers Dis. 9, 780\u2013790 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1911_CR469","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/13543784.2023.2233892","volume":"32","author":"F Panza","year":"2023","unstructured":"Panza, F. et al. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. Expert Opin. Investig. Drugs 32, 625\u2013634 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1911_CR470","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","volume":"8","author":"M Roberts","year":"2020","unstructured":"Roberts, M. et al. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease. Acta Neuropathol. Commun. 8, 13 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"1911_CR471","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","volume":"1","author":"P Novak","year":"2021","unstructured":"Novak, P. et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nat. Aging 1, 521\u2013534 (2021).","journal-title":"Nat. Aging"},{"key":"1911_CR472","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/nmt-2021-0022","volume":"11","author":"CL Reading","year":"2021","unstructured":"Reading, C. L., Ahlem, C. N. & Murphy, M. F. NM101 Phase III study of NE3107 in Alzheimer\u2019s disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegener. Dis. Manag. 11, 289\u2013298 (2021).","journal-title":"Neurodegener. Dis. Manag."},{"key":"1911_CR473","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14728214.2020.1808621","volume":"25","author":"M Lozupone","year":"2020","unstructured":"Lozupone, M. et al. Anti-amyloid-\u03b2 protein agents for the treatment of Alzheimer\u2019s disease: an update on emerging drugs. Expert Opin. Emerg. Drugs 25, 319\u2013335 (2020).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"1911_CR474","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200785","volume":"217","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model. J. Exp. Med. 217, e20200785 (2020).","journal-title":"J. Exp. Med."},{"key":"1911_CR475","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2217\/nmt-2021-0019","volume":"11","author":"M Ettcheto","year":"2021","unstructured":"Ettcheto, M. et al. Masitinib for the treatment of Alzheimer\u2019s disease. Neurodegener. Dis. Manag. 11, 263\u2013276 (2021).","journal-title":"Neurodegener. Dis. Manag."},{"key":"1911_CR476","doi-asserted-by":"publisher","first-page":"102193","DOI":"10.1016\/j.arr.2024.102193","volume":"94","author":"S Maheshwari","year":"2024","unstructured":"Maheshwari, S. et al. Navigating the dementia landscape: Biomarkers and emerging therapies. Ageing Res. Rev. 94, 102193 (2024).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR477","doi-asserted-by":"publisher","first-page":"e1002660","DOI":"10.1371\/journal.pmed.1002660","volume":"15","author":"B Lawlor","year":"2018","unstructured":"Lawlor, B. et al. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 15, e1002660 (2018).","journal-title":"PLoS Med."},{"key":"1911_CR478","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.1021\/acs.jmedchem.2c00335","volume":"65","author":"D Padhi","year":"2022","unstructured":"Padhi, D. & Govindaraju, T. Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer\u2019s Disease. J. Med. Chem. 65, 7088\u20137105 (2022).","journal-title":"J. Med. Chem."},{"key":"1911_CR479","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/17460441.2022.2033724","volume":"17","author":"R Cacabelos","year":"2022","unstructured":"Cacabelos, R. What have we learnt from past failures in Alzheimer\u2019s disease drug discovery? Expert Opin. Drug Discov. 17, 309\u2013323 (2022).","journal-title":"Expert Opin. Drug Discov."},{"key":"1911_CR480","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1002\/alz.13084","volume":"19","author":"BP Imbimbo","year":"2023","unstructured":"Imbimbo, B. P., Watling, M., Imbimbo, C. & Nistic\u00f2, R. Plasma ATN(I) classification and precision pharmacology in Alzheimer\u2019s disease. Alzheimers Dement. 19, 4729\u20134734 (2023).","journal-title":"Alzheimers Dement."},{"key":"1911_CR481","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2022.01.016","volume":"27","author":"SA Tatulian","year":"2022","unstructured":"Tatulian, S. A. Challenges and hopes for Alzheimer\u2019s disease. Drug Discov. Today 27, 1027\u20131043 (2022).","journal-title":"Drug Discov. Today"},{"key":"1911_CR482","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jalz.2018.02.007","volume":"14","author":"DP Goldman","year":"2018","unstructured":"Goldman, D. P., Fillit, H. & Neumann, P. Accelerating Alzheimer\u2019s disease drug innovations from the research pipeline to patients. Alzheimers Dement. 14, 833\u2013836 (2018).","journal-title":"Alzheimers Dement."},{"key":"1911_CR483","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/s41591-022-02062-0","volume":"28","author":"S Moutinho","year":"2022","unstructured":"Moutinho, S. The long road to a cure for Alzheimer\u2019s disease is paved with failures. Nat. Med. 28, 2228\u20132231 (2022).","journal-title":"Nat. Med."},{"key":"1911_CR484","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/med.21624","volume":"40","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Advance of sporadic Alzheimer\u2019s disease animal models. Med. Res. Rev. 40, 431\u2013458 (2020).","journal-title":"Med. Res. Rev."},{"key":"1911_CR485","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3233\/JAD-230326","volume":"94","author":"ZD Xia","year":"2023","unstructured":"Xia, Z. D. et al. Pathogenesis, Animal Models, and Drug Discovery of Alzheimer\u2019s Disease. J. Alzheimers Dis. 94, 1265\u20131301 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR486","doi-asserted-by":"publisher","first-page":"a006320","DOI":"10.1101\/cshperspect.a006320","volume":"2","author":"FM LaFerla","year":"2012","unstructured":"LaFerla, F. M. & Green, K. N. Animal models of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006320 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1911_CR487","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.24272\/j.issn.2095-8137.2022.289","volume":"43","author":"ZY Chen","year":"2022","unstructured":"Chen, Z. Y. & Zhang, Y. Animal models of Alzheimer\u2019s disease: Applications, evaluation, and perspectives. Zool. Res. 43, 1026\u20131040 (2022).","journal-title":"Zool. Res."},{"key":"1911_CR488","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.3390\/ijms21228828","volume":"21","author":"Y Luo","year":"2020","unstructured":"Luo, Y. & Li, H. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). Int J. Mol. Sci. 21, 8828 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR489","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ijc.33989","volume":"151","author":"CS Liu","year":"2022","unstructured":"Liu, C. S. et al. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses. Int. J. Cancer 151, 275\u2013286 (2022).","journal-title":"Int. J. Cancer"},{"key":"1911_CR490","doi-asserted-by":"publisher","first-page":"114516","DOI":"10.1016\/j.ejmech.2022.114516","volume":"238","author":"J Yu","year":"2022","unstructured":"Yu, J., Zhang, C. & Song, C. Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances. Eur. J. Med. Chem. 238, 114516 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR491","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/jpm11050336","volume":"11","author":"M Ghiboub","year":"2021","unstructured":"Ghiboub, M. et al. Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives. J. Pers. Med. 11, 336 (2021).","journal-title":"J. Pers. Med."},{"key":"1911_CR492","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1021\/acschemneuro.8b00252","volume":"10","author":"XL Hu","year":"2019","unstructured":"Hu, X. L. et al. Stereoisomers of Schisandrin B Are Potent ATP Competitive GSK-3beta Inhibitors with Neuroprotective Effects against Alzheimer\u2019s Disease: Stereochemistry and Biological Activity. ACS Chem. Neurosci. 10, 996\u20131007 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"1911_CR493","doi-asserted-by":"publisher","first-page":"8709","DOI":"10.3390\/ijms21228709","volume":"21","author":"I Rippin","year":"2020","unstructured":"Rippin, I. et al. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site. Int J. Mol. Sci. 21, 8709 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR494","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","volume":"148","author":"E Beurel","year":"2015","unstructured":"Beurel, E., Grieco, S. F. & Jope, R. S. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharm. Ther. 148, 114\u2013131 (2015).","journal-title":"Pharm. Ther."},{"key":"1911_CR495","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1021\/acschemneuro.8b00010","volume":"9","author":"Z Liang","year":"2018","unstructured":"Liang, Z. & Li, Q. X. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3beta Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones. ACS Chem. Neurosci. 9, 1166\u20131183 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"1911_CR496","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/biom10121683","volume":"10","author":"O Silva-Garcia","year":"2020","unstructured":"Silva-Garcia, O. et al. GSK3alpha: An Important Paralog in Neurodegenerative Disorders and Cancer. Biomolecules 10, 1683 (2020).","journal-title":"Biomolecules"},{"key":"1911_CR497","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1021\/acschemneuro.2c00476","volume":"14","author":"B Amaral","year":"2023","unstructured":"Amaral, B. et al. Elucidation of the GSK3alpha Structure Informs the Design of Novel, Paralog-Selective Inhibitors. ACS Chem. Neurosci. 14, 1080\u20131094 (2023).","journal-title":"ACS Chem. Neurosci."},{"key":"1911_CR498","doi-asserted-by":"publisher","first-page":"114301","DOI":"10.1016\/j.ejmech.2022.114301","volume":"236","author":"J Wei","year":"2022","unstructured":"Wei, J. et al. Development of inhibitors targeting glycogen synthase kinase-3\u03b2 for human diseases: Strategies to improve selectivity. Eur. J. Med. Chem. 236, 114301 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR499","doi-asserted-by":"publisher","first-page":"9600","DOI":"10.1021\/acs.jmedchem.9b01030","volume":"62","author":"V Bernard-Gauthier","year":"2019","unstructured":"Bernard-Gauthier, V. et al. Structural Basis for Achieving GSK-3beta Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery. J. Med. Chem. 62, 9600\u20139617 (2019).","journal-title":"J. Med. Chem."},{"key":"1911_CR500","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.129074","volume":"259","author":"YW Wu","year":"2024","unstructured":"Wu, Y. W. et al. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule. Int J. Biol. Macromol. 259, 129074 (2024).","journal-title":"Int J. Biol. Macromol."},{"key":"1911_CR501","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1523\/JNEUROSCI.2551-21.2022","volume":"42","author":"I Fernandez Bessone","year":"2022","unstructured":"Fernandez Bessone, I. et al. DYRK1A regulates the bidirectional axonal transport of APP in human-derived neurons. J. Neurosci. 42, 6344\u20136358 (2022).","journal-title":"J. Neurosci."},{"key":"1911_CR502","doi-asserted-by":"publisher","first-page":"9355","DOI":"10.3390\/ijms23169355","volume":"23","author":"E Deboever","year":"2022","unstructured":"Deboever, E., Fistrovich, A., Hulme, C. & Dunckley, T. The Omnipresence of DYRK1A in Human Diseases. Int J. Mol. Sci. 23, 9355 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR503","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113948","volume":"227","author":"Y Miyazaki","year":"2022","unstructured":"Miyazaki, Y. et al. Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A. Eur. J. Med. Chem. 227, 113948 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR504","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1039\/b703830p","volume":"37","author":"AV Bieliauskas","year":"2008","unstructured":"Bieliauskas, A. V. & Pflum, M. K. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 37, 1402\u20131413 (2008).","journal-title":"Chem. Soc. Rev."},{"key":"1911_CR505","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3389\/fphar.2020.00537","volume":"11","author":"S Shukla","year":"2020","unstructured":"Shukla, S. & Tekwani, B. L. Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation. Front. Pharm. 11, 537 (2020).","journal-title":"Front. Pharm."},{"key":"1911_CR506","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1750-1326-8-7","volume":"8","author":"C Sim\u00f5es-Pires","year":"2013","unstructured":"Sim\u00f5es-Pires, C. et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol. Neurodegener. 8, 7 (2013).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR507","doi-asserted-by":"publisher","first-page":"1168848","DOI":"10.3389\/fimmu.2023.1168848","volume":"14","author":"QQ Zhang","year":"2023","unstructured":"Zhang, Q. Q., Zhang, W. J. & Chang, S. HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation. Front. Immunol. 14, 1168848 (2023).","journal-title":"Front. Immunol."},{"key":"1911_CR508","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1021\/acs.jmedchem.8b01090","volume":"62","author":"K V\u00f6gerl","year":"2019","unstructured":"V\u00f6gerl, K. et al. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors. J. Med. Chem. 62, 1138\u20131166 (2019).","journal-title":"J. Med. Chem."},{"key":"1911_CR509","doi-asserted-by":"publisher","first-page":"113874","DOI":"10.1016\/j.ejmech.2021.113874","volume":"226","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer\u2019s disease: A review (2010-2020). Eur. J. Med. Chem. 226, 113874 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR510","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.ejmech.2017.10.040","volume":"143","author":"XX Wang","year":"2018","unstructured":"Wang, X. X., Wan, R. Z. & Liu, Z. P. Recent advances in the discovery of potent and selective HDAC6 inhibitors. Eur. J. Med. Chem. 143, 1406\u20131418 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR511","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113821","volume":"225","author":"XX Wang","year":"2021","unstructured":"Wang, X. X. et al. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer\u2019s disease. Eur. J. Med. Chem. 225, 113821 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR512","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"T Liang","year":"2023","unstructured":"Liang, T. et al. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm. Sin. B 13, 2425\u20132463 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"1911_CR513","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1021\/acs.jmedchem.0c01940","volume":"64","author":"F He","year":"2021","unstructured":"He, F. et al. Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer\u2019s Disease Mouse Model. J. Med. Chem. 64, 3794\u20133812 (2021).","journal-title":"J. Med. Chem."},{"key":"1911_CR514","doi-asserted-by":"publisher","first-page":"7087","DOI":"10.1021\/acs.jmedchem.8b00151","volume":"61","author":"HY Lee","year":"2018","unstructured":"Lee, H. Y. et al. 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer\u2019s Disease Phenotypes. J. Med. Chem. 61, 7087\u20137102 (2018).","journal-title":"J. Med. Chem."},{"key":"1911_CR515","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1021\/acsmedchemlett.0c00028","volume":"11","author":"E Cescon","year":"2020","unstructured":"Cescon, E. et al. Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 delta Inhibitors. ACS Med. Chem. Lett. 11, 1168\u20131174 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"1911_CR516","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/biomedicines9101431","volume":"9","author":"H Cho","year":"2021","unstructured":"Cho, H. & Hah, J.-M. J. B. A perspective on the development of c-jun N-terminal kinase inhibitors as therapeutics for alzheimer\u2019s disease: Investigating structure through docking studies. Biomedicines 9, 1431 (2021).","journal-title":"Biomedicines"},{"key":"1911_CR517","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.bmc.2013.02.021","volume":"21","author":"MH Kim","year":"2013","unstructured":"Kim, M. H. et al. Syntheses and biological evaluation of 1-heteroaryl-2-aryl-1H-benzimidazole derivatives as c-Jun N-terminal kinase inhibitors with neuroprotective effects. Bioorg. Med. Chem. 21, 2271\u20132285 (2013).","journal-title":"Bioorg. Med. Chem."},{"key":"1911_CR518","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3390\/ijms21051698","volume":"21","author":"M Jang","year":"2020","unstructured":"Jang, M. et al. Discovery of 1-Pyrimidinyl-2-Aryl-4,6-Dihydropyrrolo [3,4-d]Imidazole-5(1H)-Carboxamide as a Novel JNK Inhibitor. Int J. Mol. Sci. 21, 1698 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR519","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114894","volume":"245","author":"J Jun","year":"2023","unstructured":"Jun, J. et al. Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer\u2019s disease. Eur. J. Med. Chem. 245, 114894 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR520","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1039\/D2CS00200K","volume":"51","author":"RG Guenette","year":"2022","unstructured":"Guenette, R. G. et al. Target and tissue selectivity of PROTAC degraders. Chem. Soc. Rev. 51, 5740\u20135756 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"1911_CR521","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1039\/D0MD00154F","volume":"11","author":"F Sutanto","year":"2020","unstructured":"Sutanto, F., Konstantinidou, M. & D\u00f6mling, A. Covalent inhibitors: a rational approach to drug discovery. RSC Med. Chem. 11, 876\u2013884 (2020).","journal-title":"RSC Med. Chem."},{"key":"1911_CR522","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1021\/acsmedchemlett.0c00028","volume":"11","author":"E Cescon","year":"2020","unstructured":"Cescon, E. et al. Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 \u03b4 Inhibitors. ACS Med. Chem. Lett. 11, 1168\u20131174 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"1911_CR523","doi-asserted-by":"publisher","first-page":"5120230","DOI":"10.1155\/2020\/5120230","volume":"2020","author":"S Maramai","year":"2020","unstructured":"Maramai, S., Benchekroun, M., Gabr, M. T. & Yahiaoui, S. Multitarget Therapeutic Strategies for Alzheimer\u2019s Disease: Review on Emerging Target Combinations. Biomed. Res. Int. 2020, 5120230 (2020).","journal-title":"Biomed. Res. Int."},{"key":"1911_CR524","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2270781","volume":"38","author":"D Zou","year":"2023","unstructured":"Zou, D. et al. Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer\u2019s disease. J. Enzym. Inhib. Med. Chem. 38, 2270781 (2023).","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"1911_CR525","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","volume":"143","author":"NM Raghavendra","year":"2018","unstructured":"Raghavendra, N. M. et al. Dual or multi-targeting inhibitors: The next generation anticancer agents. Eur. J. Med. Chem. 143, 1277\u20131300 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR526","doi-asserted-by":"publisher","first-page":"113492","DOI":"10.1016\/j.ejmech.2021.113492","volume":"221","author":"JPS Ferreira","year":"2021","unstructured":"Ferreira, J. P. S. et al. Dual-target compounds for Alzheimer\u2019s disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). Eur. J. Med. Chem. 221, 113492 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR527","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1080\/13880209.2022.2102657","volume":"60","author":"S Miao","year":"2022","unstructured":"Miao, S. et al. Aaptamine - a dual acetyl - and butyrylcholinesterase inhibitor as potential anti-Alzheimer\u2019s disease agent. Pharm. Biol. 60, 1502\u20131510 (2022).","journal-title":"Pharm. Biol."},{"key":"1911_CR528","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.3390\/molecules25173915","volume":"25","author":"GF Makhaeva","year":"2020","unstructured":"Makhaeva, G. F. et al. New Hybrids of 4-Amino-2,3-polymethylene-quinoline and p-Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Alzheimer\u2019s Disease Treatment. Molecules 25, 3915 (2020).","journal-title":"Molecules"},{"key":"1911_CR529","doi-asserted-by":"publisher","first-page":"110990","DOI":"10.1016\/j.jinorgbio.2019.110990","volume":"205","author":"AM Bondzic","year":"2020","unstructured":"Bondzic, A. M. et al. Aminoalcoholate-driven tetracopper(II) cores as dual acetyl and butyrylcholinesterase inhibitors: Experimental and theoretical elucidation of mechanism of action. J. Inorg. Biochem. 205, 110990 (2020).","journal-title":"J. Inorg. Biochem."},{"key":"1911_CR530","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1021\/acs.jmedchem.0c01775","volume":"64","author":"E Viayna","year":"2021","unstructured":"Viayna, E. et al. Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP\/PS1 Mice. J. Med. Chem. 64, 812\u2013839 (2021).","journal-title":"J. Med. Chem."},{"key":"1911_CR531","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.bioorg.2018.09.010","volume":"81","author":"Q He","year":"2018","unstructured":"He, Q. et al. Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer\u2019s disease: Design, synthesis and biological evaluation. Bioorg. Chem. 81, 512\u2013528 (2018).","journal-title":"Bioorg. Chem."},{"key":"1911_CR532","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1021\/acschemneuro.2c00520","volume":"13","author":"X Li","year":"2022","unstructured":"Li, X. et al. Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer\u2019s Disease. ACS Chem. Neurosci. 13, 3488\u20133501 (2022).","journal-title":"ACS Chem. Neurosci."},{"key":"1911_CR533","doi-asserted-by":"publisher","first-page":"e1474","DOI":"10.1212\/WNL.0000000000008239","volume":"93","author":"LS Schneider","year":"2019","unstructured":"Schneider, L. S. et al. Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. Neurology 93, e1474\u2013e1484 (2019).","journal-title":"Neurology"},{"key":"1911_CR534","doi-asserted-by":"publisher","first-page":"13098","DOI":"10.3390\/ijms232113098","volume":"23","author":"N Stern","year":"2022","unstructured":"Stern, N. et al. Dual Inhibitors of AChE and BACE-1 for Reducing Abeta in Alzheimer\u2019s Disease: From In Silico to In Vivo. Int. J. Mol. Sci. 23, 13098 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1911_CR535","doi-asserted-by":"publisher","first-page":"102033","DOI":"10.1016\/j.arr.2023.102033","volume":"90","author":"MG Fronza","year":"2023","unstructured":"Fronza, M. G., Alves, D., Pratic\u00f2, D. & Savegnago, L. The neurobiology and therapeutic potential of multi-targeting \u03b2-secretase, glycogen synthase kinase 3\u03b2 and acetylcholinesterase in Alzheimer\u2019s disease. Ageing Res. Rev. 90, 102033 (2023).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR536","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1021\/acsmedchemlett.7b00463","volume":"9","author":"XY Jiang","year":"2018","unstructured":"Jiang, X. Y. et al. Dual GSK-3beta\/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer\u2019s Disease Drug Discovery. ACS Med. Chem. Lett. 9, 171\u2013176 (2018).","journal-title":"ACS Med. Chem. Lett."},{"key":"1911_CR537","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112751","volume":"207","author":"X Jiang","year":"2020","unstructured":"Jiang, X. et al. Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer\u2019s disease. Eur. J. Med. Chem. 207, 112751 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR538","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1007\/s11030-022-10504-7","volume":"26","author":"R Swetha","year":"2022","unstructured":"Swetha, R. et al. Combined ligand-based and structure-based design of PDE 9A inhibitors against Alzheimer\u2019s disease. Mol. Divers. 26, 2877\u20132892 (2022).","journal-title":"Mol. Divers."},{"key":"1911_CR539","doi-asserted-by":"publisher","first-page":"1019187","DOI":"10.3389\/fnagi.2022.1019187","volume":"14","author":"J Sheng","year":"2022","unstructured":"Sheng, J. et al. Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer\u2019s disease. Front. Aging Neurosci. 14, 1019187 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"1911_CR540","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114503","volume":"238","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4\/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer\u2019s disease. Eur. J. Med. Chem. 238, 114503 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR541","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","volume":"15","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J. Hematol. Oncol. 15, 89 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"1911_CR542","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/biom10020325","volume":"10","author":"J Jakubik","year":"2020","unstructured":"Jakubik, J. & El-Fakahany, E. E. Current Advances in Allosteric Modulation of Muscarinic Receptors. Biomolecules 10, 325 (2020).","journal-title":"Biomolecules"},{"key":"1911_CR543","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie, X. et al. Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials. Signal Transduct. Target Ther. 8, 335 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR544","doi-asserted-by":"publisher","first-page":"NS20210004","DOI":"10.1042\/NS20210004","volume":"6","author":"L Dwomoh","year":"2022","unstructured":"Dwomoh, L., Tejeda, G. S. & Tobin, A. B. Targeting the M1 muscarinic acetylcholine receptor in Alzheimer\u2019s disease. Neuronal. Signal 6, NS20210004 (2022).","journal-title":"Neuronal. Signal"},{"key":"1911_CR545","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.606656","volume":"11","author":"ET van der Westhuizen","year":"2020","unstructured":"van der Westhuizen, E. T. et al. Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias. Front. Pharm. 11, 606656 (2020).","journal-title":"Front. Pharm."},{"key":"1911_CR546","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13578-021-00738-7","volume":"12","author":"JE Luo","year":"2022","unstructured":"Luo, J. E. & Li, Y. M. Turning the tide on Alzheimer\u2019s disease: modulation of \u03b3-secretase. Cell Biosci. 12, 2 (2022).","journal-title":"Cell Biosci."},{"key":"1911_CR547","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s44318-024-00057-w","volume":"43","author":"B De Strooper","year":"2024","unstructured":"De Strooper, B. & Karran, E. New precision medicine avenues to the prevention of Alzheimer\u2019s disease from insights into the structure and function of \u03b3-secretases. EMBO J. 43, 887\u2013903 (2024).","journal-title":"EMBO J."},{"key":"1911_CR548","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202560","volume":"218","author":"KD Rynearson","year":"2021","unstructured":"Rynearson, K. D. et al. Preclinical validation of a potent \u03b3-secretase modulator for Alzheimer\u2019s disease prevention. J. Exp. Med. 218, e20202560 (2021).","journal-title":"J. Exp. Med."},{"key":"1911_CR549","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11062-7","volume":"10","author":"SA Hollingsworth","year":"2019","unstructured":"Hollingsworth, S. A. et al. Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs. Nat. Commun. 10, 3289 (2019).","journal-title":"Nat. Commun."},{"key":"1911_CR550","doi-asserted-by":"publisher","first-page":"106764","DOI":"10.1016\/j.phrs.2023.106764","volume":"191","author":"AV Terry Jr.","year":"2023","unstructured":"Terry, A. V. Jr., Jones, K. & Bertrand, D. Nicotinic acetylcholine receptors in neurological and psychiatric diseases. Pharm. Res. 191, 106764 (2023).","journal-title":"Pharm. Res."},{"key":"1911_CR551","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.tins.2021.11.006","volume":"45","author":"AC Letsinger","year":"2022","unstructured":"Letsinger, A. C., Gu, Z. & Yakel, J. L. \u03b17 nicotinic acetylcholine receptors in the hippocampal circuit: taming complexity. Trends Neurosci. 45, 145\u2013157 (2022).","journal-title":"Trends Neurosci."},{"key":"1911_CR552","unstructured":"Sinha, N. et al. Discovery of Novel, Potent, Brain-Permeable, and Orally Efficacious Positive Allosteric Modulator of \u03b17 Nicotinic Acetylcholine Receptor [4-(5-(4-Chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide]: Structure-Activity Relationship and Preclinical Characterization. J. Med. Chem. 63, 944\u2013960 (2020)."},{"key":"1911_CR553","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1124\/jpet.117.243774","volume":"364","author":"E Kurimoto","year":"2018","unstructured":"Kurimoto, E. et al. An Approach to Discovering Novel Muscarinic M(1) Receptor Positive Allosteric Modulators with Potent Cognitive Improvement and Minimized Gastrointestinal Dysfunction. J. Pharm. Exp. Ther. 364, 28\u201337 (2018).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1911_CR554","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1021\/acschemneuro.8b00613","volume":"10","author":"M J\u00f6rg","year":"2019","unstructured":"J\u00f6rg, M. et al. 6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M(1) mAChR: The Determinants of Allosteric Activity. ACS Chem. Neurosci. 10, 1099\u20131114 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"1911_CR555","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1021\/acs.jmedchem.7b01812","volume":"61","author":"JCC Dallagnol","year":"2018","unstructured":"Dallagnol, J. C. C. et al. Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor with Weak Agonist Activity and Diverse Modulatory Profiles. J. Med. Chem. 61, 2875\u20132894 (2018).","journal-title":"J. Med. Chem."},{"key":"1911_CR556","doi-asserted-by":"publisher","first-page":"e0261696","DOI":"10.1371\/journal.pone.0261696","volume":"17","author":"H Querfurth","year":"2022","unstructured":"Querfurth, H. et al. A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro. PLoS One 17, e0261696 (2022).","journal-title":"PLoS One"},{"key":"1911_CR557","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3390\/cells10081871","volume":"10","author":"M Dahlstrom","year":"2021","unstructured":"Dahlstrom, M. et al. Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction. Cells 10, 1871 (2021).","journal-title":"Cells"},{"key":"1911_CR558","first-page":"778","volume":"10","author":"K \u00d6nnestam","year":"2023","unstructured":"\u00d6nnestam, K. et al. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects. J. Prev. Alzheimers Dis. 10, 778\u2013789 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1911_CR559","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.976435","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Advances in RIPK1 kinase inhibitors. Front. Pharm. 13, 976435 (2022).","journal-title":"Front. Pharm."},{"key":"1911_CR560","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1113\/JP280875","volume":"600","author":"C Geoffroy","year":"2022","unstructured":"Geoffroy, C., Paoletti, P. & Mony, L. Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential. J. Physiol. 600, 233\u2013259 (2022).","journal-title":"J. Physiol."},{"key":"1911_CR561","doi-asserted-by":"publisher","first-page":"7541","DOI":"10.3390\/ijms24087541","volume":"24","author":"B Balboni","year":"2023","unstructured":"Balboni, B. et al. GSK-3\u03b2 Allosteric Inhibition: A Dead End or a New Pharmacological Frontier? Int. J. Mol. Sci. 24, 7541 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1911_CR562","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nrd746","volume":"1","author":"A Christopoulos","year":"2002","unstructured":"Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198\u2013210 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1911_CR563","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2021.10.011","volume":"43","author":"M Mannes","year":"2022","unstructured":"Mannes, M., Martin, C., Menet, C. & Ballet, S. Wandering beyond small molecules: peptides as allosteric protein modulators. Trends Pharm. Sci. 43, 406\u2013423 (2022).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR564","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1021\/acs.jmedchem.8b01651","volume":"62","author":"Q Coughlin","year":"2019","unstructured":"Coughlin, Q. et al. Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases. J. Med. Chem. 62, 5979\u20136002 (2019).","journal-title":"J. Med. Chem."},{"key":"1911_CR565","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1002\/mog2.56","volume":"2","author":"L Zheng","year":"2023","unstructured":"Zheng, L. et al. Development of covalent inhibitors: Principle, design, and application in cancer. MedComm. Oncol. 2, e56 (2023).","journal-title":"MedComm. Oncol."},{"key":"1911_CR566","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/d41573-020-00161-6","volume":"19","author":"M Cully","year":"2020","unstructured":"Cully, M. Novel chemistry for covalent inhibitors. Nat. Rev. Drug Discov. 19, 754 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1911_CR567","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1039\/C9CS00720B","volume":"49","author":"A Abdeldayem","year":"2020","unstructured":"Abdeldayem, A. et al. Advances in covalent kinase inhibitors. Chem. Soc. Rev. 49, 2617\u20132687 (2020).","journal-title":"Chem. Soc. Rev."},{"key":"1911_CR568","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1039\/C4MT00252K","volume":"7","author":"MR Jones","year":"2015","unstructured":"Jones, M. R. et al. Modulation of the A\u03b2 peptide aggregation pathway by KP1019 limits A\u03b2-associated neurotoxicity. Metallomics 7, 129\u2013135 (2015).","journal-title":"Metallomics"},{"key":"1911_CR569","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.958399","volume":"9","author":"A Eden","year":"2022","unstructured":"Eden, A. et al. Covalent fragment inhibits intramembrane proteolysis. Front. Mol. Biosci. 9, 958399 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"1911_CR570","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw0930","volume":"363","author":"R Zhou","year":"2019","unstructured":"Zhou, R. et al. Recognition of the amyloid precursor protein by human \u03b3-secretase. Science 363, eaaw0930 (2019).","journal-title":"Science"},{"key":"1911_CR571","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/ph16050663","volume":"16","author":"D Schaefer","year":"2023","unstructured":"Schaefer, D. & Cheng, X. Recent Advances in Covalent Drug Discovery. Pharmaceuticals 16, 663 (2023).","journal-title":"Pharmaceuticals"},{"key":"1911_CR572","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccell.2019.12.009","volume":"37","author":"F McCormick","year":"2020","unstructured":"McCormick, F. Sticking it to KRAS: Covalent Inhibitors Enter the Clinic. Cancer Cell 37, 3\u20134 (2020).","journal-title":"Cancer Cell"},{"key":"1911_CR573","doi-asserted-by":"publisher","first-page":"13408","DOI":"10.1002\/anie.201601091","volume":"55","author":"TA Baillie","year":"2016","unstructured":"Baillie, T. A. Targeted Covalent Inhibitors for Drug Design. Angew. Chem. Int. Ed. Engl. 55, 13408\u201313421 (2016).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1911_CR574","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11064-022-03722-w","volume":"48","author":"S Bhatia","year":"2023","unstructured":"Bhatia, S., Singh, M., Singh, T. & Singh, V. Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer\u2019s Disease. Neurochem. Res. 48, 13\u201325 (2023).","journal-title":"Neurochem. Res."},{"key":"1911_CR575","doi-asserted-by":"publisher","first-page":"11454","DOI":"10.1021\/acs.jmedchem.2c00844","volume":"65","author":"Y Fang","year":"2022","unstructured":"Fang, Y. et al. Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy. J. Med. Chem. 65, 11454\u201311477 (2022).","journal-title":"J. Med. Chem."},{"key":"1911_CR576","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113889","volume":"226","author":"L Qu","year":"2021","unstructured":"Qu, L. et al. Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer\u2019s disease. Eur. J. Med. Chem. 226, 113889 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR577","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tips.2022.01.005","volume":"43","author":"CD Sibley","year":"2022","unstructured":"Sibley, C. D. & Schneekloth, J. S. Heterobifunctional molecules tackle targeted protein dephosphorylation. Trends Pharm. Sci. 43, 263\u2013265 (2022).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR578","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1021\/jacs.2c11706","volume":"145","author":"Z Hu","year":"2023","unstructured":"Hu, Z. et al. Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality. J. Am. Chem. Soc. 145, 4045\u20134055 (2023).","journal-title":"J. Am. Chem. Soc"},{"key":"1911_CR579","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1016\/j.apsb.2023.05.035","volume":"13","author":"D Wu","year":"2023","unstructured":"Wu, D. et al. Small molecules targeting protein-protein interactions for cancer therapy. Acta Pharm. Sin. B 13, 4060\u20134088 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"1911_CR580","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/bs.apcsb.2023.11.005","volume":"139","author":"V Kumar","year":"2024","unstructured":"Kumar, V. & Roy, K. Protein-protein interaction network analysis for the identification of novel multi-target inhibitors and target miRNAs against Alzheimer\u2019s disease. Adv. Protein Chem. Struct. Biol. 139, 405\u2013467 (2024).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"1911_CR581","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad237","volume":"24","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. Network integration and protein structural binding analysis of neurodegeneration-related interactome. Brief. Bioinform. 24, bbad237 (2023).","journal-title":"Brief. Bioinform."},{"key":"1911_CR582","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2174\/1568026619666190304153353","volume":"19","author":"A Ganeshpurkar","year":"2019","unstructured":"Ganeshpurkar, A. et al. Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer\u2019s Disease. Curr. Top. Med. Chem. 19, 501\u2013533 (2019).","journal-title":"Curr. Top. Med. Chem."},{"key":"1911_CR583","doi-asserted-by":"publisher","first-page":"573259","DOI":"10.3389\/fchem.2020.573259","volume":"8","author":"BL Santini","year":"2020","unstructured":"Santini, B. L. & Zacharias, M. Rapid in silico Design of Potential Cyclic Peptide Binders Targeting Protein-Protein Interfaces. Front. Chem. 8, 573259 (2020).","journal-title":"Front. Chem."},{"key":"1911_CR584","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3390\/ijms20102383","volume":"20","author":"AC Lee","year":"2019","unstructured":"Lee, A. C., Harris, J. L., Khanna, K. K. & Hong, J. H. A Comprehensive Review on Current Advances in Peptide Drug Development and Design. Int. J. Mol. Sci. 20, 2383 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1911_CR585","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13024-022-00550-y","volume":"17","author":"P Zhao","year":"2022","unstructured":"Zhao, P. et al. LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. Mol. Neurodegener. 17, 44 (2022).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR586","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/s41557-018-0147-z","volume":"10","author":"Q Cao","year":"2018","unstructured":"Cao, Q. et al. Inhibiting amyloid-\u03b2 cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design. Nat. Chem. 10, 1213\u20131221 (2018).","journal-title":"Nat. Chem."},{"key":"1911_CR587","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2021.103630","volume":"114","author":"K Lao","year":"2021","unstructured":"Lao, K. et al. Identification of novel A\u03b2-LilrB2 inhibitors as potential therapeutic agents for Alzheimer\u2019s disease. Mol. Cell Neurosci. 114, 103630 (2021).","journal-title":"Mol. Cell Neurosci."},{"key":"1911_CR588","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.3390\/molecules25102439","volume":"25","author":"L Ciccone","year":"2020","unstructured":"Ciccone, L. et al. The Positive Side of the Alzheimer\u2019s Disease Amyloid Cross-Interactions: The Case of the A\u03b2 1-42 Peptide with Tau, TTR, CysC, and ApoA1. Molecules 25, 2439 (2020).","journal-title":"Molecules"},{"key":"1911_CR589","doi-asserted-by":"publisher","first-page":"113847","DOI":"10.1016\/j.ejmech.2021.113847","volume":"226","author":"EY Cotrina","year":"2021","unstructured":"Cotrina, E. Y. et al. Targeting transthyretin in Alzheimer\u2019s disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer\u2019s disease. Eur. J. Med. Chem. 226, 113847 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1911_CR590","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104172","volume":"103","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. Direct inhibition of Keap1-Nrf2 Protein-Protein interaction as a potential therapeutic strategy for Alzheimer\u2019s disease. Bioorg. Chem. 103, 104172 (2020).","journal-title":"Bioorg. Chem."},{"key":"1911_CR591","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102793","volume":"64","author":"Y Sun","year":"2023","unstructured":"Sun, Y. et al. A potent phosphodiester Keap1-Nrf2 protein-protein interaction inhibitor as the efficient treatment of Alzheimer\u2019s disease. Redox Biol. 64, 102793 (2023).","journal-title":"Redox Biol."},{"key":"1911_CR592","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1021\/acs.jmedchem.2c00457","volume":"65","author":"N Georgakopoulos","year":"2022","unstructured":"Georgakopoulos, N. et al. Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode. J. Med. Chem. 65, 7380\u20137398 (2022).","journal-title":"J. Med. Chem."},{"key":"1911_CR593","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.tips.2016.05.008","volume":"37","author":"AE Modell","year":"2016","unstructured":"Modell, A. E., Blosser, S. L. & Arora, P. S. Systematic Targeting of Protein-Protein Interactions. Trends Pharm. Sci. 37, 702\u2013713 (2016).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR594","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/prd.12429","volume":"89","author":"G Jungbauer","year":"2022","unstructured":"Jungbauer, G. et al. Periodontal microorganisms and Alzheimer disease\u2013A causative relationship? Periodontol. 2000 89, 59\u201382 (2022).","journal-title":"Periodontol. 2000"},{"key":"1911_CR595","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/prd.12389","volume":"87","author":"MI Ryder","year":"2021","unstructured":"Ryder, M. I. & Xenoudi, P. Alzheimer disease and the periodontal patient: New insights, connections, and therapies. Periodontol. 2000 87, 32\u201342 (2021).","journal-title":"Periodontol. 2000"},{"key":"1911_CR596","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13024-022-00559-3","volume":"17","author":"T Ganz","year":"2022","unstructured":"Ganz, T., Fainstein, N. & Ben-Hur, T. When the infectious environment meets the AD brain. Mol. Neurodegener. 17, 53 (2022).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR597","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/jama.2020.4085","volume":"324","author":"AL Komaroff","year":"2020","unstructured":"Komaroff, A. L. Can Infections Cause Alzheimer Disease? JAMA 324, 239\u2013240 (2020).","journal-title":"JAMA"},{"key":"1911_CR598","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.tim.2020.03.003","volume":"28","author":"ME Marcocci","year":"2020","unstructured":"Marcocci, M. E. et al. Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection. Trends Microbiol. 28, 808\u2013820 (2020).","journal-title":"Trends Microbiol"},{"key":"1911_CR599","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jinf.2021.12.004","volume":"84","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. MAMDC2, a gene highly expressed in microglia in experimental models of Alzheimers Disease, positively regulates the innate antiviral response during neurotropic virus infection. J. Infect. 84, 187\u2013204 (2022).","journal-title":"J. Infect."},{"key":"1911_CR600","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02376-8","volume":"13","author":"MA Albaret","year":"2023","unstructured":"Albaret, M. A. et al. HSV-1 cellular model reveals links between aggresome formation and early step of Alzheimer\u2019s disease. Transl. Psychiatry 13, 86 (2023).","journal-title":"Transl. Psychiatry"},{"key":"1911_CR601","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41380-024-02428-5","volume":"29","author":"M Zhao","year":"2024","unstructured":"Zhao, M. et al. Microbial infection promotes amyloid pathology in a mouse model of Alzheimer\u2019s disease via modulating \u03b3-secretase. Mol. Psychiatry 29, 1491\u20131500 (2024).","journal-title":"Mol. Psychiatry"},{"key":"1911_CR602","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-220800","volume":"91","author":"M Golzari-Sorkheh","year":"2023","unstructured":"Golzari-Sorkheh, M., Weaver, D. F. & Reed, M. A. COVID-19 as a Risk Factor for Alzheimer\u2019s Disease. J. Alzheimers Dis. 91, 1\u201323 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR603","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3233\/JAD-220717","volume":"89","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Association of COVID-19 with New-Onset Alzheimer\u2019s Disease. J. Alzheimers Dis. 89, 411\u2013414 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"1911_CR604","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/alz.12296","volume":"17","author":"Q Wang","year":"2021","unstructured":"Wang, Q., Davis, P. B., Gurney, M. E. & Xu, R. COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 17, 1297\u20131306 (2021).","journal-title":"Alzheimers Dement."},{"key":"1911_CR605","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41392-022-01118-4","volume":"7","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients. Signal Transduct. Target Ther. 7, 261 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR606","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/brain\/awab337","volume":"144","author":"N Magusali","year":"2021","unstructured":"Magusali, N. et al. A genetic link between risk for Alzheimer\u2019s disease and severe COVID-19 outcomes via the OAS1 gene. Brain 144, 3727\u20133741 (2021).","journal-title":"Brain"},{"key":"1911_CR607","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41421-022-00458-3","volume":"8","author":"G Ma","year":"2022","unstructured":"Ma, G. et al. SARS-CoV-2 Spike protein S2 subunit modulates \u03b3-secretase and enhances amyloid-\u03b2 production in COVID-19 neuropathy. Cell Discov. 8, 99 (2022).","journal-title":"Cell Discov."},{"key":"1911_CR608","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25855-2","volume":"12","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Highly efficient intercellular spreading of protein misfolding mediated by viral ligand-receptor interactions. Nat. Commun. 12, 5739 (2021).","journal-title":"Nat. Commun."},{"key":"1911_CR609","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.arr.2024.102195","volume":"94","author":"HM Mansour","year":"2024","unstructured":"Mansour, H. M. The interference between SARS-COV-2 and Alzheimer\u2019s disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed pandemic. Ageing Res. Rev. 94, 102195 (2024).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR610","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-023-01324-4","volume":"15","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer\u2019s disease: findings based on urine proteomics and machine learning. Alzheimers Res. Ther. 15, 191 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"1911_CR611","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40120-019-00168-1","volume":"8","author":"NJ Ashton","year":"2019","unstructured":"Ashton, N. J., Ide, M., Zetterberg, H. & Blennow, K. Salivary biomarkers for Alzheimer\u2019s disease and related disorders. Neurol. Ther. 8, 83\u201394 (2019).","journal-title":"Neurol. Ther."},{"key":"1911_CR612","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/alz.12006","volume":"16","author":"J Alber","year":"2020","unstructured":"Alber, J. et al. Developing retinal biomarkers for the earliest stages of Alzheimer\u2019s disease: What we know, what we don\u2019t, and how to move forward. Alzheimers Dement. 16, 229\u2013243 (2020).","journal-title":"Alzheimers Dement."},{"key":"1911_CR613","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.tips.2023.06.010","volume":"44","author":"FW Pun","year":"2023","unstructured":"Pun, F. W., Ozerov, I. V. & Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharm. Sci. 44, 561\u2013572 (2023).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR614","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101379","volume":"5","author":"F Cheng","year":"2024","unstructured":"Cheng, F. et al. Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer\u2019s disease. Cell Rep. Med. 5, 101379 (2024).","journal-title":"Cell Rep. Med."},{"key":"1911_CR615","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111717","volume":"41","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer\u2019s disease. Cell Rep. 41, 111717 (2022).","journal-title":"Cell Rep."},{"key":"1911_CR616","doi-asserted-by":"publisher","first-page":"102172","DOI":"10.1016\/j.arr.2023.102172","volume":"93","author":"C Geng","year":"2024","unstructured":"Geng, C., Wang, Z. & Tang, Y. Machine learning in Alzheimer\u2019s disease drug discovery and target identification. Ageing Res. Rev. 93, 102172 (2024).","journal-title":"Ageing Res. Rev."},{"key":"1911_CR617","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.1002\/alz.13390","volume":"19","author":"LM Winchester","year":"2023","unstructured":"Winchester, L. M. et al. Artificial intelligence for biomarker discovery in Alzheimer\u2019s disease and dementia. Alzheimers Dement. 19, 5860\u20135871 (2023).","journal-title":"Alzheimers Dement."},{"key":"1911_CR618","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31037-5","volume":"13","author":"S Qiu","year":"2022","unstructured":"Qiu, S. et al. Multimodal deep learning for Alzheimer\u2019s disease dementia assessment. Nat. Commun. 13, 3404 (2022).","journal-title":"Nat. Commun."},{"key":"1911_CR619","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"PT Francis","year":"1999","unstructured":"Francis, P. T., Palmer, A. M., Snape, M. & Wilcock, G. K. The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66, 137\u2013147 (1999).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1911_CR620","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ana.410100203","volume":"10","author":"PJ Whitehouse","year":"1981","unstructured":"Whitehouse, P. J. et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10, 122\u2013126 (1981).","journal-title":"Ann. Neurol."},{"key":"1911_CR621","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0006-3223(92)90227-Q","volume":"31","author":"BA Lawlor","year":"1992","unstructured":"Lawlor, B. A. & Davis, K. L. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer\u2019s disease? Biol. Psychiatry 31, 337\u2013350 (1992).","journal-title":"Biol. Psychiatry"},{"key":"1911_CR622","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharm. Sci. 12, 383\u2013388 (1991).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR623","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0140-6736(92)91780-C","volume":"340","author":"B Regland","year":"1992","unstructured":"Regland, B. & Gottfries, C. G. The role of amyloid beta-protein in Alzheimer\u2019s disease. Lancet 340, 467\u2013469 (1992).","journal-title":"Lancet"},{"key":"1911_CR624","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/0166-2236(93)90078-Z","volume":"16","author":"M Goedert","year":"1993","unstructured":"Goedert, M. Tau protein and the neurofibrillary pathology of Alzheimer\u2019s disease. Trends Neurosci. 16, 460\u2013465 (1993).","journal-title":"Trends Neurosci."},{"key":"1911_CR625","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0962-8924(98)01368-3","volume":"8","author":"EM Mandelkow","year":"1998","unstructured":"Mandelkow, E. M. & Mandelkow, E. Tau in Alzheimer\u2019s disease. Trends Cell Biol. 8, 425\u2013427 (1998).","journal-title":"Trends Cell Biol."},{"key":"1911_CR626","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1176\/ajp.151.8.1105","volume":"151","author":"PS Aisen","year":"1994","unstructured":"Aisen, P. S. & Davis, K. L. Inflammatory mechanisms in Alzheimer\u2019s disease: implications for therapy. Am. J. Psychiatry 151, 1105\u20131113 (1994).","journal-title":"Am. J. Psychiatry"},{"key":"1911_CR627","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner, F. L., Ransohoff, R. M. & Becher, B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16, 358\u2013372 (2015).","journal-title":"Nat. Rev. Neurosci."},{"key":"1911_CR628","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1136\/gutjnl-2021-326269","volume":"71","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Gut microbiota regulate Alzheimer\u2019s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut 71, 2233\u20132252 (2022).","journal-title":"Gut"},{"key":"1911_CR629","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13024-023-00595-7","volume":"18","author":"S Chandra","year":"2023","unstructured":"Chandra, S., Sisodia, S. S. & Vassar, R. J. The gut microbiome in Alzheimer\u2019s disease: what we know and what remains to be explored. Mol. Neurodegener. 18, 9 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1911_CR630","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1126\/science.8073293","volume":"265","author":"AI Bush","year":"1994","unstructured":"Bush, A. I. et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265, 1464\u20131467 (1994).","journal-title":"Science"},{"key":"1911_CR631","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tips.2009.05.002","volume":"30","author":"P Zatta","year":"2009","unstructured":"Zatta, P., Drago, D., Bolognin, S. & Sensi, S. L. Alzheimer\u2019s disease, metal ions and metal homeostatic therapy. Trends Pharm. Sci. 30, 346\u2013355, (2009).","journal-title":"Trends Pharm. Sci."},{"key":"1911_CR632","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41582-022-00749-z","volume":"19","author":"M Tzioras","year":"2023","unstructured":"Tzioras, M., McGeachan, R. I., Durrant, C. S. & Spires-Jones, T. L. Synaptic degeneration in Alzheimer disease. Nat. Rev. Neurol. 19, 19\u201338 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"1911_CR633","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1911_CR634","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10787-019-00580-x","volume":"27","author":"D Kaur","year":"2019","unstructured":"Kaur, D., Sharma, V. & Deshmukh, R. Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer\u2019s disease. Inflammopharmacology 27, 663\u2013677 (2019).","journal-title":"Inflammopharmacology"},{"key":"1911_CR635","doi-asserted-by":"publisher","first-page":"13880","DOI":"10.3390\/ijms241813880","volume":"24","author":"S Stanca","year":"2023","unstructured":"Stanca, S., Rossetti, M. & Bongioanni, P. Astrocytes as Neuroimmunocytes in Alzheimer\u2019s Disease: A Biochemical Tool in the Neuron-Glia Crosstalk along the Pathogenetic Pathways. Int J. Mol. Sci. 24, 13880 (2023).","journal-title":"Int J. Mol. Sci."},{"key":"1911_CR636","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(18)30490-3","volume":"18","author":"AM Arranz","year":"2019","unstructured":"Arranz, A. M. & De Strooper, B. The role of astroglia in Alzheimer\u2019s disease: pathophysiology and clinical implications. Lancet Neurol. 18, 406\u2013414 (2019).","journal-title":"Lancet Neurol."},{"key":"1911_CR637","doi-asserted-by":"publisher","first-page":"104956","DOI":"10.1016\/j.neuint.2021.104956","volume":"145","author":"S Sarkar","year":"2021","unstructured":"Sarkar, S. & Biswas, S. C. Astrocyte subtype-specific approach to Alzheimer\u2019s disease treatment. Neurochem Int. 145, 104956 (2021).","journal-title":"Neurochem Int."},{"key":"1911_CR638","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41577-023-00837-1","volume":"23","author":"M Colonna","year":"2023","unstructured":"Colonna, M. The biology of TREM receptors. Nat. Rev. Immunol. 23, 580\u2013594 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1911_CR639","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2021.111438","volume":"195","author":"Q Qin","year":"2021","unstructured":"Qin, Q. et al. TREM2, microglia, and Alzheimer\u2019s disease. Mech. Ageing Dev. 195, 111438 (2021).","journal-title":"Mech. Ageing Dev."},{"key":"1911_CR640","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland, T. K. & Colonna, M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol. 14, 667\u2013675 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"1911_CR641","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1084\/jem.20171529","volume":"215","author":"WM Song","year":"2018","unstructured":"Song, W. M. et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J. Exp. Med. 215, 745\u2013760 (2018).","journal-title":"J. Exp. Med."},{"key":"1911_CR642","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809027","volume":"10","author":"CB Lessard","year":"2018","unstructured":"Lessard, C. B. et al. High-affinity interactions and signal transduction between A\u03b2 oligomers and TREM2. EMBO Mol. Med. 10, e9027 (2018).","journal-title":"EMBO Mol. Med."},{"key":"1911_CR643","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1016\/j.cell.2022.09.033","volume":"185","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. TREM2 drives microglia response to amyloid-\u03b2 via SYK-dependent and -independent pathways. Cell 185, 4153\u20134169.e4119 (2022).","journal-title":"Cell"},{"key":"1911_CR644","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.811210","volume":"13","author":"A Custodia","year":"2021","unstructured":"Custodia, A. et al. Endothelial Progenitor Cells and Vascular Alterations in Alzheimer\u2019s Disease. Front Aging Neurosci. 13, 811210 (2021).","journal-title":"Front Aging Neurosci."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01911-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01911-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01911-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T06:06:46Z","timestamp":1725775606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-01911-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":644,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1038\/s41392-024-01911-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}